"Publication Number","Title","Abstract","Application Year","Application Date","Publication Year","Publication Date","First Claim","Inventor(s)","Assignee(s)","IPC(s)","UPC(s)","CPC(s)","Cited By (3 Years)","Total Cited By","Cited By","Total Cites","Cites"
"US5403712","Transcription cofactor assay"," Methods and compositions are provided for producing and utilizing nucleic acid and peptide sequences associated with cofactors which bind to transcription factors to enhance transcriptional activity of the transcriptional factors and maintain the transcriptional factors as dimers. The compositions can be used for modulating expression of genes, particularly coordinately regulated genes, as evidenced by the combination of the transcription factors HNF-1.alpha. and -1.beta. with the cofactor DCoH. ","1993","1993-11-22","1995","1995-04-04","""A method for screening for the presence of expression in a mammalian cell of a transcription cofactor characterized by:having molecular weight in the range of 5-25 kd;having a domain of from about 20-50 amino acids, which is lipophilic in having a plurality of hydrophobic aliphatic and aromatic amino acids;existing as dimers in a nuclear extract;capable of enhancing dimerization of transcription factors; andnot having a specific binding affinity for the DNA sequence to which said transcription factors bind;said method comprising:combining under hybridizing conditions a nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 with the lysate from said mammalian cell; anddetecting the presence of duplexes of messenger RNA formed with said nucleic acid sequence as indicative of expression of said transcription cofactor.""","Gerald R. Crabtree | Dirk B. Mendel","The Board of Trustees of the Leland Stanford Junior University","C12Q1/68","435/6 | 935/78 | 935/77 | 435/6.12 | 435/6.1 | 435/6.18 | 506/9","C12N15/67 | C07K14/4702 | C07K2319/00 | C07K2319/61 | C07K2319/71 | C07K2319/81","13","14","US6696256 | US6410228 | US6924113 | US7960536 | US6821737 | US5750336 | US6410239 | US6395478 | US6187533 | US7981842 | US9334537 | US6083693 | US6750198 | US6057101","0"," "
"US5770581","Gene transcription and ionizing radiation: methods and compositions"," The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided. ","1995","1995-06-07","1998","1998-06-23","""A process of inhibiting growth of a tumor comprising the steps of: (a) delivering to said tumor a therapeutically effective amount of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes a polypeptide having the ability to inhibit growth of a tumor cell, which encoding region is operatively linked to a transcription-terminating region; and (b) exposing said cell to an effective expression-inducing dose of ionizing radiations; whereby the polypeptide is expressed and inhibits the growth of said tumor.""","Ralph R. Weichselbaum | Dennis E. Hallahan | Vikas P. Sukhatme | Donald W. Kufe","ARCH Development Corporation | Dana-Farber Cancer Institute, Inc.","A61K48/00","935/36 | 514/44 | 536/241 | 435/172.3 | 514/44R | 435/447 | 435/455 | 536/24.1","A61K41/0023 | A61K48/00 | C07K14/52 | C07K14/525 | C07K14/82 | C12N15/63 | C12N15/635 | C12N15/67 | C12N15/85 | G03G15/2025 | A61K38/00 | C07K2319/00 | C07K2319/61 | C07K2319/71 | C07K2319/81 | C12N2830/001 | C12N2830/002 | C12N2830/008 | C12N2830/85 | G03G2215/2083","15","15","US7214368 | US6080728 | US6867036 | US7105292 | US9745314 | US7041653 | US7112338 | US7135192 | US6156736 | US8034791 | US6756055 | US6794137 | US6120799 | US7238369 | US6579522","2","""US""""4667063             """" | US""""5571797             """""""
"US6007988","Binding proteins for recognition of DNA"," Disclosed are libraries of DNA sequences encoding zinc finger binding motifs for display on a particle, together with methods of designing zinc finger binding polypeptides for binding to a particular target sequence and, inter alia, use of designed zinc finger polypeptides for various in vitro or in vivo applications. ","1997","1997-06-02","1999","1999-12-28","""A library of DNA sequences, each sequence encoding a zinc finger polypeptide for display, the zinc finger polypeptide comprising at least one zinc finger having partially randomised allocation of amino acids, the partially randomised zinc finger having a random allocation of amino acids at positions -1, +2, +3 and +6 and at least one of positions +1, +5 or +8, position +1 being the first amino acid in the .alpha.-helix of the zinc finger.""","Yen Choo | Aaron Klug | Isidro Sanchez-Garcia","Medical Research Council","C12Q1/68 | C07H21/04","435/6 | 536/234 | 435/6.12 | 506/9 | 536/23.4","C07K19/00 | C07K14/4702 | C07K14/4705 | C12N15/1037 | C12Q1/68 | C40B40/02 | C07K2319/00 | C07K2319/09 | C07K2319/30 | C07K2319/81","200","200","US9206404 | US9074224 | US7972854 | US9150879 | US9567573 | US9255250 | US7759059 | US8034598 | US8936936 | US7696334 | US8772009 | US6977154 | US9574211 | US8883417 | US8399218 | US6824978 | US8680021 | US9322036 | US7951925 | US6989269 | US9717759 | US8735153 | US9670271 | US9512444 | USRE39229 | US9616090 | US9222105 | US7622250 | US6785613 | US7153949 | US8623618 | US8106255 | US7943553 | US8597912 | US9200266 | US7273923 | US9115409 | US9491934 | US7928195 | US9631187 | US9523098 | US9434776 | US7013219 | US9695442 | US9447434 | US8945868 | USRE45795 | US8771985 | US6733970 | US8313925 | US9376685 | US6872548 | USRE42211 | US7893022 | US9005973 | US8071564 | US7241574 | US9394545 | US9322005 | US9487802 | US8110379 | US8153399 | US9388426 | US7235354 | US9506120 | US7914796 | US8383766 | US7407776 | US9175280 | US6453242 | US8592645 | US9161995 | US7217509 | US9493750 | US9045763 | US7262055 | US8012946 | US8524500 | USRE45721 | US7732196 | US8772025 | US8409861 | US7514257 | US7888121 | US8772453 | US7262054 | US7220719 | US7939327 | US7358085 | US7788044 | US9567604 | US8703489 | US9376689 | US9150847 | US6610489 | US7070934 | US7521241 | US7705139 | US8841260 | US7605140 | US8551945 | US7045304 | US7163824 | US8329986 | USRE42150 | US9217026 | US6794136 | US6479626 | US9267123 | US8349810 | US8563314 | US9145565 | US6503717 | US8822221 | US9234188 | US7026462 | US6806062 | US9493779 | US6599692 | US7067317 | US9567609 | US7700523 | US9402879 | US6979539 | US7285416 | US9629930 | US9512446 | US7985887 | US8871905 | US6410248 | US8921112 | US8268618 | US9624509 | US6689558 | US8895264 | US7851216 | US9499597 | US8586526 | US9594075 | US8569253 | US7947469 | US7998679 | US6607882 | US8617807 | US7585849 | US7923542 | US9597357 | US8956828 | US8962281 | US7795209 | US6933113 | US9234016 | US8426164 | US6746838 | US9234187 | US9376484 | US7566533 | US7919313 | US7361635 | US8524874 | US7097978 | US9458205 | US6534261 | US8524221 | US9631186 | US9289451 | US9121072 | US9249428 | US9255259 | US7030215 | US7534775 | US9394531 | US7491531 | US8912138 | US9260726 | US9163245 | US7177766 | US6866997 | US9816074 | US9783827 | US6511808 | US8980583 | US7560440 | US8088598 | US8889390 | US9566352 | US6899892 | US6790941 | US9187758 | US8772008 | US9238803 | US8771986 | US6903185 | US9567603 | US9631201 | US9624498 | US9267154 | US9650648 | US6777185 | US7595376","1","US5498530"
"US6010860","Method for site-specific integration of nucleic acids and related products"," Chimeric proteins are provided comprising a first domain that attaches said chimeric protein to a target nucleic acid, and a second domain that integrates donor nucleic acid into a target nucleic acid. Also provided are nucleic acid constructs, recombinant vectors encoding invention chimeric proteins, recombinant retroviruses, and related methods. ","1998","1998-12-01","2000","2000-01-04","""A chimeric protein comprising:a first domain, which domain comprises a sequence-specific DNA-binding domain or which domain comprises a protein-binding domain which indirectly attaches said chimeric protein to a specific recognition sequence of a nucleic acid through attachment of said protein-binding domain to at least one other protein which facilitates attachment of said chimeric protein to said specific recognition sequence of a nucleic acid; anda second domain, which domain comprises an integrase protein or a fragment of said integrase protein which integrates donor nucleic acid into target nucleic acid,wherein the first domain is heterologous to the second domain and the carboxyl terminus of the first domain is joined to the amino terminus of the second domain or the carboxyl terminus of the second domain is joined to the amino terminus of the first domain.""","Frederic D. Bushman","The Salk Institute for Biological Studies","C07K14/155 | C12Q1/68 | C12Q1/02 | C12N15/87 | C07K14/05 | C07K14/15 | C07K14/16 | C12N9/12","435/468 | 435/194 | 530/300 | 435/6 | 435/471 | 530/350 | 435/455 | 435/456 | 435/463 | 435/29 | 435/5 | 435/6.13","C07K14/005 | C07K14/46 | C12N15/62 | C12N15/90 | C12Q1/68 | C07K2319/00 | C07K2319/10 | C07K2319/21 | C07K2319/42 | C07K2319/50 | C07K2319/73 | C07K2319/80 | C07K2319/81 | C12N2740/15022 | C12N2740/16222","1","1","US7798645","3","US5252479 | US4405712 | US4650764"
"US6063625","Regulated transcription of targeted genes and other biological events",""" Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta. chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active """"dimerizers"""" or """"de-dimerizers"""", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as """"universal drugs"""". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein). ""","1998","1998-09-16","2000","2000-05-16","""A method for regulating expression of a target gene in a muscle cell comprising(I) providing a muscle cell comprising(i) a first nucleic acid encoding a first chimeric protein comprising(a) at least one ligand-binding domain which binds to a selected ligand having one or more of the following characteristics:(i) the ligand is not a protein;(ii) the ligand has a molecular weight less than 5 kD; and(iii) the ligand is membrane permeable; and(b) a transcriptional activation domain, which is heterologous with respect to at least one ligand-binding domain; and(ii) a second nucleic acid encoding a second chimeric protein comprising(a) a least one ligand-binding domain which binds to the selected ligand to form a ligand cross-linked protein complex including the first and the second chimeric protein; and(b) a nucleic acid-binding domain, which is heterologous with respect to at least one ligand-binding domain of the second chimeric protein,wherein the ligand binds to at least one ligand bind domain of each of the first and the second chimeric proteins to form a ligand cross-linked protein complex which regulates transcription of a target gene operably linked to a transcriptional regulatory element to which the ligand cross-linked protein complex binds; and(II) exposing the muscle cell to the ligand in an amount effective to regulate transcription of the target gene.""","Gerald R. Crabtree | Stuart L. Schreiber | David M. Spencer, Jr. | Thomas J. Wandless | Steffan N. Ho | Peter J. Belshaw","President and Fellows of Harvard College | Board of Trustees of Leland S. Stanford Jr. University","C12N15/85 | C12N15/86 | C12N15/00","435/325 | 435/455 | 435/370 | 435/456 | 435/375 | 435/366 | 435/465","C07D498/18 | A61K47/6425 | C07F5/025 | C07H19/01 | C07K7/645 | C07K14/395 | C07K14/705 | C07K14/7051 | C07K14/71 | C12N15/62 | C12N15/63 | C12P15/00 | A61K38/00 | C07K2319/00 | C07K2319/02 | C07K2319/03 | C07K2319/035 | C07K2319/09 | C07K2319/20 | C07K2319/32 | C07K2319/42 | C07K2319/43 | C07K2319/60 | C07K2319/71 | C07K2319/715 | C07K2319/81 | C07K2319/90","8","8","US9528088 | US8617884 | US6972193 | US7572631 | US9719106 | US7541184 | US8084596 | US7135550","1","US5171671"
"US6511808","Methods for designing exogenous regulatory molecules","Methods for the design of exogenous regulatory molecules, comprising a DNA-binding domain and a functional domain, are provided. The methods rely on the identification, isolation and characterization of regulatory DNA sequences obtained on the basis of their accessibility in cellular chromatin.","2001","2001-04-27","2003","2003-01-28","""A method for designing one or more exogenous regulatory molecules for regulating a gene of interest, the method comprising:(a) providing one or more collections of polynucleotide sequences, each collection comprising a plurality of polynucleotide sequences corresponding to accessible regions of cellular chromatin in a sample; (b) identifying one or more sequence elements from the collection, wherein the one or more sequence elements are potential regulatory sequences for the gene of interest; and (c) preparing an exogenous regulatory molecule that comprises a DNA binding domain and a functional domain that activates or represses transcription of the gene of interest, wherein said preparing comprises selecting the DNA binding domain, the functional domain or both the DNA binding domain and the functional domain based upon the identified sequence elements.""","Alan P. Wolffe | Fyodor Urnov | Dmitry M. Guschin | Trevor N. Collingwood | Xiaoyong Li | Brian H. Johnstone","SANGAMO BIOSCIENCES, INC.","C12Q1/68","435/6.12 | 435/6.13","G06F19/22 | C07K14/4702 | C12N15/1034 | C12N15/1051 | C12N15/62 | C12N15/63 | C12N15/66 | C12Q1/6811 | C12Q1/6811 | C07K2319/02 | C07K2319/09 | C07K2319/24 | C07K2319/43 | C07K2319/71 | C07K2319/75 | C07K2319/81 | G06F19/28 | C12Q2531/113 | C12Q2525/191 | C12Q2522/101","10","10","US9567603 | US7514257 | US8685737 | US9499837 | US9567604 | US7297477 | US9701971 | US9512446 | US9574208 | US8704041","18","US5422251 | US6013453 | US5998140 | US5525471 | US5789538 | US6090947 | US5585245 | US5695937 | US5866330 | US5958738 | US5501964 | US5935830 | US5610053 | US5176996 | US5766891 | US5731178 | US5436142 | US6007988"
"US6534261","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","1999","1999-01-12","2003","2003-03-18","""A method of inhibiting transcription of an endogenous cellular gene in an isolated cell, the method comprising the steps of:administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first zinc finger protein, wherein said first zinc finger protein is engineered, wherein said polynucleotide sequence is operably linked to a promoter, and wherein the nucleic acid molecule expresses the first zinc finger protein in the cell; and contacting a first target site in the endogenous cellular gene with the first zinc finger protein, wherein the Kd of the zinc finger protein is less than about 25 nM; thereby inhibiting transcription of the endogenous cellular gene by at least about 20%.""","George N. Cox, III | Casey Case | Stephen P. Eisenberg | Eric Edward Jarvis | Sharon Kaye Spratt","SANGAMO BIOSCIENCES, INC.","C12Q1/68","536/241 | 435/29 | 536/235 | 435/6.12 | 536/23.5 | 536/24.1","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","170","170","US9115409 | US9506915 | US9428756 | US9376689 | US9163245 | US8071370 | US9175280 | US9402879 | US9695442 | US8841260 | US7785792 | US9526784 | US8563314 | US8313925 | US8399218 | US7163824 | US9506120 | US9616090 | US9289447 | US8772009 | US8461303 | US9566352 | US6872548 | US8772453 | US9458205 | US9249428 | US8071285 | US8349810 | US8551945 | US9631186 | US9176139 | US9499597 | US8592645 | US9717759 | US8871905 | US8012946 | US7732196 | US8034598 | US8921112 | US7781645 | US8153399 | US8927700 | US8110379 | US7067317 | US8771986 | US8597912 | US7795209 | US8071564 | US9631187 | US9267123 | US8168180 | US7407776 | US9420770 | US7972854 | US7888121 | US9145565 | US9163284 | US7919313 | US9234016 | US9487802 | US9567573 | US8268618 | US9187758 | US8772008 | US8329986 | US8936936 | US9279816 | US9594075 | US8623618 | US7595306 | US9255259 | US9376484 | US9150847 | US9629930 | US8679485 | US7943731 | US8956828 | US8524221 | US9394531 | US9068179 | US8815823 | US9260726 | US9289451 | US7928195 | US8771985 | US7947469 | US7605140 | US7521241 | US8962281 | US9458439 | US8912138 | US7560440 | US8586526 | US9074224 | US8895264 | US9493750 | US8945868 | US8658167 | US9523098 | US9567609 | US8822221 | US9267154 | US9200266 | US9624498 | US9597357 | US7914796 | US9783827 | US9816074 | US8703489 | US9376685 | US9005973 | US8163494 | US8409861 | US9512444 | US9388430 | US8680246 | US9434776 | USRE42211 | US8524500 | US7595376 | US9255250 | US7358085 | US7378510 | US9322036 | US9394545 | US7893022 | US9493779 | US9522936 | US7514257 | US9322037 | US9121072 | USRE45721 | US9574211 | US7985887 | US7153949 | US7285416 | US9150879 | US8980583 | US7951925 | US7262055 | US9631201 | US9217026 | US9222105 | US8772025 | US7329728 | US7851216 | US9447434 | US8704041 | US7442784 | US8569253 | US7262054 | US9359599 | US9328144 | US9322005 | US8512990 | US9107935 | US9045763 | US9161995 | US7151201 | US6903185 | US9650648 | US8106255 | US9322006 | US6919204 | US8460674 | US9670271 | US8889390 | US9206404 | US9388426 | US7534775","34","US6001885 | US5223409 | US5096814 | US5674738 | US6007988 | US5302519 | US5702914 | US5869618 | US5916794 | US5487994 | US5356802 | US5639592 | US5871907 | US5578483 | US5096815 | US5348864 | US5939538 | US6013453 | US5340739 | US5324819 | US5871902 | US5403484 | US4990607 | US5498530 | US5792640 | US5376530 | US5324638 | US5243041 | US5436150 | US5597693 | US5350840 | US5324818 | US5972615 | US5198346"
"US6607882","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","2000","2000-01-06","2003","2003-08-19","""A method of activating expression of a developmentally silenced endogenous cellular gene in a cell; the method comprising the steps of:(a) administering a nucleic acid to the cell, wherein the nucleic acid comprises a sequence encoding a first zinc finger protein operably linked to a promoter, wherein the first zinc finger protein is engineered; and (b) contacting a first target site in the endogenous cellular gene with the first zinc finger protein, wherein the Kd of the zinc finger protein is less than about 25 nM; wherein said contacting results in activation of expression of the endogenous cellular gene to at least about 150%.""","George N. Cox, III | Casey Case | Stephen P. Eisenberg | Eric Edward Jarvis | Sharon Kaye Spratt","SANGAMO BIOSCIENCES, INC.","C12Q1/68","435/455 | 435/320.1 | 536/241 | 536/231 | 435/468 | 536/234 | 435/6.12 | 536/23.1 | 536/23.4 | 536/24.1","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","97","97","US9322037 | US9670271 | US9567609 | US9267123 | US9322005 | US8034598 | US7253273 | US8772008 | US8569253 | US8771985 | US9255259 | US8148129 | US8623618 | US8703489 | US7939327 | US7947469 | US7785792 | US9115409 | US7795209 | US8962281 | US7070934 | US9650648 | US9163284 | US9359599 | US9631186 | US9175280 | US7358085 | US9005973 | US8841260 | US8524221 | US9388426 | US9597357 | US9566352 | US9420770 | US8871905 | US7893022 | US9222105 | US9493750 | US7407776 | US8772025 | US7951925 | US8563314 | US6919204 | US9506120 | US8153399 | US9121072 | US9322006 | US9068179 | US8772009 | US9624498 | US7919313 | US9567573 | US8586526 | US9629930 | US8956828 | US9394545 | US9402879 | US7001768 | US9234016 | US9388430 | US9161995 | US8071370 | US8597912 | US9594075 | US9255250 | US9322036 | US9616090 | US9376484 | US8895264 | US9522936 | US9499597 | US7534775 | US9150847 | US8912138 | US9574211 | US8466267 | US8980583 | US9487802 | US7595306 | US9150879 | US9783827 | US9816074 | US7914796 | US7732196 | US9717759 | US9512444 | US9376689 | US8012946 | US9200266 | US7514257 | US8771986 | US8945868 | US9434776 | US9526784 | US9631187 | US8105827 | US8551945","37","US5096815 | US5498530 | US5871902 | US6013453 | US5487994 | US5597693 | US5356802 | US5302519 | US5972615 | US5702914 | US5792640 | US5436150 | US5403484 | US5348864 | US5674738 | US5578483 | US5830721 | US6160091 | US5916794 | US5871907 | US5340739 | US5376530 | US5324818 | US6001885 | US5639592 | US4990607 | US5869618 | US5223409 | US5324638 | US5324819 | US5243041 | US5939538 | US5198346 | US5350840 | US5096814 | US6007988 | US5789538"
"US6790941","Zinc finger protein derivatives and methods therefor","Zinc finger proteins of the Cys2His2 type represent a class of malleable DNA binding proteins which may be selected to bind diverse sequences. Typically, zinc finger proteins containing three zinc finger domains, like the murine transcription factor Zif268 and the human transcription factor Sp1, bind nine contiguous base pairs (bp). To create a class of proteins which would be generally applicable to target unique sites within complex genomes, the present invention provides a polypeptide linker that fuses two three-finger proteins. Two six-fingered proteins were created and demonstrated to bind 18 contiguous bp of DNA in a sequence specific fashion. Expression of these proteins as fusions to activation or repression domains allows transcription to be specifically up or down modulated within cells. Polydactyl zinc finger proteins are broadly applicable as genome-specific transcriptional switches in gene therapy strategies and the development of novel transgenic plants and animals. Such proteins are useful for inhibiting, activating or enhancing gene expression from a zinc finger-nucleotide binding motif containing promoter or other transcriptional control element, as well as a structural gene or RNA sequence.","2000","2000-02-09","2004","2004-09-14","""An isolated zinc finger-nucleotide binding polypeptide variant comprising at least two zinc finger modules wherein the amino acid sequence of at least one zinc finger module of said variant has at least one amino acid sequence modification, wherein said variant is a mutagenized form of a zinc finger binding protein and binds a polynucleotide sequence different from a sequence bound by the zinc finger-nucleotide binding polypeptide from which the variant is derived and wherein the amino acid sequence of each zinc finger module that binds a polynucleotide sequence different from a sequence bound by the zinc finger-nucleotide binding polypeptide from which the variant is derived comprises two cysteines and two histidines, whereby both cysteines are amino proximal to both histidines.""","Carlos F. Barbas, III | Joel M. Gottesfeld | Peter E. Wright","The Scripps Research Institute","C07K1/00","435/697 | 435/320.1 | 435/455 | 435/471 | 530/358 | 530/350 | 435/252.3 | 435/325 | 536/231 | 435/235.1 | 536/232 | 435/691 | 530/400 | 435/69.1 | 435/69.7 | 536/23.1 | 536/23.2","C07K14/46 | C07K14/4702 | C12N15/62 | C12Q1/68 | G01N33/5008 | G01N33/5011 | G01N33/502 | G01N33/56988 | G01N33/68 | A61K38/00 | A61K48/00 | C07K2319/00 | C07K2319/02 | C07K2319/09 | C07K2319/24 | C07K2319/42 | C07K2319/71 | C07K2319/73 | C07K2319/735 | C07K2319/81","10","10","US7442784 | US9074224 | US7732196 | US8012946 | US8242242 | US9499837 | US7358085 | US7795209 | US9574208 | US7893022","36","US5916794 | US5223409 | US5702914 | US5597693 | US5871902 | US5348864 | US5792640 | US5789538 | US5403484 | US5674738 | US2002/0081614 | US5939538 | US5436150 | US5356802 | US6013453 | US6001885 | US5302519 | US5324818 | US5487994 | US5376530 | US6007988 | US5096814 | US5324638 | US5324819 | US5243041 | US5096815 | US5869618 | US5578483 | US6242568 | US5350840 | US5871907 | US5498530 | US5639592 | US5198346 | US5340739 | US4990607"
"US6824978","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","2000","2000-11-03","2004","2004-11-30","""A method of inhibiting expression of an endogenous cellular gene in a cell, the method comprising the step of:contacting a first target site in the endogenous cellular gene with a first zinc finger protein, wherein said first zinc finger protein is engineered and wherein the Kd of the zinc finger protein is less than about 25 nM; thereby inhibiting expression of the endogenous cellular gene.""","George N. Cox, III | Casey Case | Stephen P. Eisenberg | Eric Edward Jarvis | Sharon Kaye Spratt","SANGAMO BIOSCIENCES, INC.","C12Q1/68","530/350 | 536/234 | 435/455 | 435/468 | 435/320.1 | 435/691 | 435/6.12 | 435/6.13 | 435/69.1 | 536/23.4","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","99","99","US8771986 | US9434776 | US9566352 | US9322005 | US9717759 | US8524221 | US9005973 | US8772008 | US9017967 | US7795209 | US9175280 | US9624498 | US9567609 | US9200266 | US9506120 | US9115409 | US7285416 | US9163284 | US8680021 | US8313925 | US8895264 | US8551945 | US9121072 | US9388430 | US9402879 | US9234016 | US9322036 | US8420782 | US8962281 | US9523098 | US9255250 | US9650648 | US9074224 | US8012946 | US8440431 | US7514257 | US7893022 | US9267123 | US9376689 | US7919313 | US7070934 | US8586363 | US7914796 | US9161995 | US8772009 | US8034598 | US7273923 | US7951925 | US8450471 | US8563314 | US8586526 | US8697853 | US8440432 | US7521241 | US7705139 | US8841260 | US8703489 | US9388426 | US9260726 | US9616090 | US9068179 | US8153399 | US8470973 | US9359599 | US7732196 | US8771985 | US9493750 | US9150847 | US9353378 | US8569253 | US9322037 | US9222105 | US9522936 | US9322006 | US9574211 | US9631187 | US8329986 | US8956828 | US9499597 | US9453054 | US8597912 | US9567573 | US8912138 | US9629930 | US8945868 | US8772025 | US8623618 | US9783827 | US9816074 | US9150879 | US9255259 | US7358085 | US9526784 | US9420770 | US8148129 | US8871905 | US9597357 | US9631186 | US9394545","40","US6242568 | US5792640 | US6140466 | US6140081 | US5871902 | US5436150 | US5348864 | US5597693 | US5223409 | US5939538 | US5198346 | US5096814 | US5243041 | US5578483 | US6001885 | US4990607 | US5498530 | US5324638 | US5702914 | US5830721 | US6160091 | US5869618 | US5324819 | US5916794 | US5350840 | US5356802 | US5096815 | US5324818 | US5487994 | US5403484 | US5972615 | US5376530 | US6007988 | US5871907 | US5340739 | US5674738 | US5302519 | US6013453 | US5789538 | US5639592"
"US6933113","Modulation of endogenous gene expression in cells","Disclosed herein are methods and compositions for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","2001","2001-08-28","2005","2005-08-23","""A method of modulating expression of an endogenous cellular gene in a cell, the method comprising the step of:contacting the cell with a first polynucleotide encoding a first zinc finger protein, wherein the first zinc finger protein is a fusion protein comprising a designed or selected zinc finger protein in operative linkage with a fimctional domain, further wherein the fusion protein binds to a first target site in the gene; thereby modulating expression of the endogenous cellular gene.""","Alan P. Wolffe | Fyodor Urnov | Albert Lai | Andrew Snowden | Siyuan Tan | Philip D. Gregory","SANGAMO BIOSCIENCES, INC."," ","435/320.1 | 536/234 | 435/691 | 435/455 | 435/458 | 435/6.12 | 435/6.13 | 435/69.1 | 536/23.4","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","88","88","US9526784 | US8962281 | US9376689 | US9322037 | US8945868 | US8440432 | US8912138 | US8772009 | US9005973 | US9624498 | US7919313 | US8420782 | US9388430 | US9434776 | US8450471 | US9163284 | US9150879 | US9597357 | US8772025 | US8470973 | US9650648 | US9260726 | US8569253 | US9322005 | US9074224 | US8871905 | US9068179 | US8771986 | US7914796 | US8771985 | US9567573 | US9161995 | US9493750 | US8034598 | US8597912 | US8895264 | US9322036 | US9115409 | US9394545 | US9506120 | US9353378 | US9816074 | US9783827 | US9499597 | US9222105 | US8440431 | US8563314 | US8153399 | US9217026 | US8313925 | US9388426 | US8703489 | US9523098 | US9453054 | US9255250 | US9574211 | US8772008 | US8956828 | US8586363 | US9150847 | US9200266 | US9017967 | US9267123 | US9629930 | US8524221 | US8697853 | US8586526 | US9234016 | US9717759 | US9567609 | US9420770 | US9175280 | US9402879 | US9566352 | US9522936 | US8148129 | US9631187 | US9322006 | US9631186 | US8623618 | US9616090 | US8841260 | US7951925 | US8329986 | US9121072 | US8551945 | US9255259 | US9359599","44","US5789538 | US5376530 | US5830721 | US5340739 | US5198346 | US5436150 | US5972615 | US5096814 | US5674738 | US6001885 | US4990607 | US5871902 | US6270990 | US5348864 | US5792640 | US5356802 | US5814618 | US6140466 | US5498530 | US5223409 | US5639592 | US6242568 | US6013453 | US5602009 | US5324638 | US5302519 | US5939538 | US5487994 | US5243041 | US6004941 | US5324819 | US5578483 | US5871907 | US6007988 | US5350840 | US5597693 | US5403484 | US5324818 | US6160091 | US6140081 | US5869618 | US5096815 | US5916794 | US5702914"
"US6979539","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","2001","2001-07-02","2005","2005-12-27","""A method of inhibiting expression of an endogenous cellular pine in a cell, the method comprising the step of:administering to the cell a nucleic acid molecule comprising a polynucleotide sequence which encodes a first engineered zinc finger protein, wherein (i) said polynucleotide sequence is operably linked to a promoter, (ii) the nucleic acid molecule expresses the zinc finger protein is less cell; (iii) the zinc finger protein contacts a first target site in the endogenous cellular gene; and (iv) the Kd of the zinc finger protein is less than about 25 nM; thereby inhibiting expression of the endogenous cellular gene.""","George N. Cox, III | Casey Case | Stephen P. Eisenberg | Eric Edward Jarvis | Sharon Kaye Spratt","SANGAMO BIOSCIENCES, INC."," ","435/320.1 | 435/691 | 536/231 | 536/241 | 435/6.12 | 435/6.13 | 435/69.1 | 536/23.1 | 536/24.1","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","82","82","US8703489 | US9376689 | US9434776 | US9267123 | US9115409 | US8586363 | US8420782 | US9629930 | US8623618 | US9522936 | US9322037 | US9506120 | US8440431 | US9068179 | US8771985 | US7919313 | US9255259 | US9631187 | US9121072 | US9567573 | US9420770 | US7914796 | US9234016 | US9567609 | US9453054 | US9388426 | US9574211 | US9359599 | US8771986 | US9402879 | US9717759 | US9616090 | US8551945 | US9353378 | US8772025 | US9816074 | US9783827 | US9005973 | US9566352 | US8034598 | US8148129 | US9222105 | US9255250 | US8597912 | US9322006 | US7951925 | US9163284 | US9017967 | US8912138 | US8945868 | US8772008 | US9394545 | US8841260 | US9150847 | US9322005 | US8962281 | US9322036 | US9175280 | US8440432 | US9200266 | US9150879 | US9499597 | US9631186 | US9597357 | US8895264 | US8153399 | US8871905 | US9624498 | US8586526 | US8772009 | US9161995 | US8956828 | US8470973 | US9526784 | US8450471 | US8524221 | US9493750 | US8569253 | US8697853 | US9388430 | US9650648 | US8563314","40","US5096815 | US4990607 | US5223409 | US5356802 | US5487994 | US5348864 | US5972615 | US5830721 | US5243041 | US6140466 | US5578483 | US5376530 | US5198346 | US5939538 | US5436150 | US5403484 | US5792640 | US5869618 | US5350840 | US5498530 | US5871902 | US5096814 | US5324638 | US5789538 | US5674738 | US6013453 | US5302519 | US6001885 | US5871907 | US6160091 | US5639592 | US5340739 | US5324818 | US5597693 | US6140081 | US5916794 | US5702914 | US6007988 | US5324819 | US6242568"
"US7001768","Targeted modification of chromatin structure","Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.","2001","2001-04-27","2006","2006-02-21","""A method for altering chromatin structure in a region of interest in chromosomal cellular chromatin in an isolated cell, the method comprising the step of contacting the chromosomal cellular chromatin with a fusion molecule that binds to a binding site in the region of interest, wherein the fusion molecule comprises a DNA binding domain and at least one subunit protein of a chromatin remodeling complex or functional fragment of the subunit protein, wherein the contacting is conducted under conditions such that the structure of chromosomal chromatin is altered in the region of interest, and further wherein the fusion molecule does not regulate transcription.""","Alan P. Wolffe","SANGAMO BIOSCIENCES, INC.","C12N15/85 | C12N15/00 | C07K14/00 | C12N15/09","530/402 | 530/350 | 435/455 | 435/375","C12N15/1058 | C07K14/4702 | C12N15/102 | C12N15/1034 | C12N15/62 | C12N15/63 | C12N15/66 | C12N15/67 | C12Q1/6811 | G06F19/22 | C07K2319/00 | C07K2319/02 | C07K2319/09 | C07K2319/24 | C07K2319/43 | C07K2319/71 | C07K2319/75 | C07K2319/81 | G06F19/28","32","32","US9322005 | US9453054 | US8524874 | US8952133 | US8039587 | US8889390 | US8586526 | US8927691 | US8586363 | US8420782 | US9017967 | US8507277 | US8399218 | US8383766 | US9631201 | US9353378 | US8658393 | US8470972 | US8470973 | US8450471 | US9574208 | US9783827 | US8541550 | US8912138 | US8440431 | US8133733 | US8592645 | US8440432 | US8298529 | US8062891 | US8697853 | US9493750","5","US6183965 | US6607882 | US6153383 | US5972608 | US6015709"
"US7013219","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using engineered zinc finger proteins.","2002","2002-09-16","2006","2006-03-14","""A method for modulating expression of an endogenous gene in a cell, wherein the method comprises:a) administering to the cell a nucleic acid molecule comprising a polynucleotide sequence encoding an engineered zinc finger protein, wherein the engineered zinc finger protein comprises a plurality of zinc fingers and further wherein the amino acid sequence of at least one of the zinc fingers is obtained from the information in a database of existing zinc finger proteins and their respective binding affinities; and b) maintaining the cell under conditions in which the engineered zinc finger protein is expressed and binds to a target site in the gene.""","Casey Case | George N. Cox, III | Stephen P. Eisenberg | Qiang Liu | Edward J. Rebar","SANGAMO BIOSCIENCES, INC.","C12N15/11 | C12N5/10 | C12Q1/68 | G06F19/00","435/468 | 435/6 | 435/471 | 536/234 | 435/455 | 702/19 | 435/6.12 | 536/23.4","A61K48/005 | C07K2319/09 | C07K2319/43 | C07K2319/71 | C07K2319/81 | C12N2750/14143","85","85","US9388430 | US9376689 | US9566352 | US8771986 | US8697853 | US8148129 | US8153399 | US9567609 | US9491934 | US9650648 | US9322005 | US9017967 | US8569253 | US8524221 | US8383766 | US9175280 | US7951925 | US9068179 | US9522936 | US8912138 | US8450471 | US8034598 | US9353378 | US9631187 | US8420782 | US9526784 | US8945868 | US9161995 | US8524874 | US8772025 | US8563314 | US9453054 | US9624498 | US9222105 | US9267123 | US8551945 | US8772008 | US9200266 | US9567573 | US7914796 | US9717759 | US8597912 | US9322036 | US9322006 | US9121072 | US9631186 | US8586526 | US8470973 | US8841260 | US8586363 | US8703489 | US9115409 | US9005973 | US8440431 | US7919313 | US8440432 | US9150847 | US9629930 | US9597357 | US9493750 | US8623618 | US8895264 | US9499597 | US9420770 | US8871905 | US9163284 | US9255259 | US9255250 | US9783827 | US9816074 | US8956828 | US9394545 | US9616090 | US9574211 | US8771985 | US9388426 | US9150879 | US9359599 | US9234016 | US8772009 | US9402879 | US9434776 | US8962281 | US9506120 | US9322037","40","US5243041 | US5916794 | US5198346 | US5324638 | US4990607 | US6160091 | US5096815 | US5789538 | US5324818 | US6140081 | US5830721 | US5578483 | US6001885 | US5223409 | US5350840 | US5792640 | US5348864 | US5436150 | US5302519 | US5403484 | US5674738 | US5871902 | US5939538 | US5324819 | US6242568 | US6013453 | US6140466 | US5487994 | US5972615 | US5871907 | US5869618 | US5597693 | US5702914 | US5639592 | US5376530 | US5356802 | US5498530 | US5096814 | US6007988 | US5340739"
"US7041653","Gene transcription and ionizing radiation: methods and compositions","The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.","2000","2000-12-05","2006","2006-05-09","""A process of inhibiting growth of a tumor in a host comprising:(a) injecting into said tumor a virus vehicle comprising a therapeutically effective amount of a DNA molecule comprising a radiation inducible promoter operatively linked to an encoding reqion that encodes a tumor necrosis factor-&#x3b1; polypeptide, and (b) exposing the tumor to an effective expression-inducing dose of ionizing radiation, wherein the tumor necrosis factor-&#x3b1; polypeptide is expressed and the growth of the tumor is inhibited.""","Ralph R. Weichselbaum | Dennis E. Hallahan | Vikas P. Sukhatme | Donald W. Kufe","Dana-Farber Cancer Institute, Inc. | The University of Chicago","A01N43/04 | C07H21/04 | C12N15/63 | C07H21/02 | A01N63/00","424/932 | 536/231 | 424/931 | 536/235 | 536/241 | 435/455 | 514/44R | 424/93.1 | 424/93.2 | 536/23.1 | 536/23.5 | 536/24.1","A61K41/0023 | A61K48/00 | C07K14/52 | C07K14/525 | C07K14/82 | C12N15/63 | C12N15/635 | C12N15/67 | C12N15/85 | G03G15/2025 | A61K38/00 | C07K2319/00 | C07K2319/61 | C07K2319/71 | C07K2319/81 | C12N2830/001 | C12N2830/002 | C12N2830/008 | C12N2830/85 | G03G2215/2083","1","1","US8034791","12","US5206152 | US6156736 | US5571797 | US5817636 | US4370417 | US5770581 | US6605712 | US4835098 | US4677064 | US4833080 | US5612318 | US4667063"
"US7163824","Regulation of endogenous gene expression in cells using zinc finger proteins","The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.","2002","2002-08-15","2007","2007-01-16","""A cell comprising first and second engineered zinc finger proteins, wherein each of the zinc finger proteins further comprises an endonuclease or functional fragment thereof, and further wherein:(a) the first protein binds to a first target site; and(b) the second protein binds to a second target site.""","George N. Cox, III | Casey Case | Stephen P. Eisenberg | Eric Edward Jarvis | Sharon Kaye Spratt","SANGAMO BIOSCIENCES, INC.","C12N9/16 | C12N15/82 | C12N15/85 | C12N15/63","435/196 | 435/455 | 435/372 | 435/410 | 435/366 | 435/325","A01K67/0275 | A61K48/005 | C07K14/47 | C07K14/52 | C12N15/63 | C12N15/67 | C12N15/8216 | C12N15/85 | C12Q1/66 | C12Q1/6897 | G01N33/5091 | A01K2217/05 | A61K48/00 | C07K2319/00 | C07K2319/71 | C07K2319/81 | C12N2830/002 | C12N2830/005 | C12N2830/008 | C12N2830/85","82","82","US9068179 | US8420782 | US8153399 | US9322006 | US8551945 | US8586363 | US9566352 | US9150847 | US9388426 | US9522936 | US8563314 | US9121072 | US9255250 | US8623618 | US9322036 | US9631187 | US9267123 | US9650648 | US9567573 | US8569253 | US8912138 | US9499597 | US8771986 | US9234016 | US8945868 | US9402879 | US8772008 | US9526784 | US8440431 | US8034598 | US8841260 | US8586526 | US9616090 | US9506120 | US9388430 | US9567609 | US7919313 | US9376689 | US9453054 | US9322037 | US9359599 | US9150879 | US9161995 | US9175280 | US8771985 | US7914796 | US8450471 | US9434776 | US9322005 | US9005973 | US8148129 | US8597912 | US9783827 | US9816074 | US8772025 | US9353378 | US8956828 | US8703489 | US9493750 | US9222105 | US8440432 | US9624498 | US8895264 | US8962281 | US8871905 | US8470973 | US9115409 | US9717759 | US8524221 | US8697853 | US9629930 | US8772009 | US9597357 | US9574211 | US7951925 | US9458205 | US9631186 | US9163284 | US9200266 | US9255259 | US9017967 | US9394545","42","US5487994 | US5674738 | US5324638 | US5403484 | US5436150 | US4990607 | US5350840 | US6534261 | US5792640 | US5871907 | US5702914 | US6140466 | US5243041 | US5096815 | US5597693 | US5869618 | US5639592 | US5376530 | US5223409 | US6242568 | US5356802 | US5302519 | US5096814 | US6007988 | US5972615 | US6001885 | US6265196 | US5939538 | US5324818 | US6013453 | US5340739 | US5348864 | US5916794 | US5830721 | US5578483 | US5871902 | US5789538 | US5198346 | US5324819 | US6140081 | US6160091 | US5498530"
"US7217509","Databases of regulatory sequences; methods of making and using same","Methods and compositions for the identification, isolation and characterization of regulatory DNA sequences in a cell of interest are provided. Also provided are libraries of regulatory sequences obtained according to the methods, and databases comprising collections of regulatory sequences for a particular cell of interest. In addition, various uses for the regulatory sequences so obtained, and uses for the databases of regulatory sequences, are provided. Also disclosed are computer systems and computer program products for utilizing the databases to conduct various genetic analyses, and uses of accessible regulatory sequences in the design of vectors bearing transgenes.","2001","2001-04-27","2007","2007-05-15","""A method for preparing a library of regulatory DNA sequences from a cell, the method comprising:(a) providing a cell nucleus, wherein the nucleus comprises cellular chromatin;(b) contacting the nucleus with a first enzyme, wherein the first enzyme reacts with accessible regions of cellular chromatin;(c) deproteinizing the cellular chromatin to generate deproteinized DNA;(d) contacting the deproteinized DNA with a second enzyme to generate a plurality of different DNA fragments;(e) contacting the DNA fragments obtained in step (d) with a population of vector molecules, wherein the vector molecules comprise a first end that is compatible with the first enzyme and a second end that is compatible with the second enzyme, under conditions favorable to ligation of compatible ends; and(f) selecting polynucleotides comprising a DNA fragment ligated to a vector molecule.""","Alan P. Wolffe | Fyodor Urnov","SANGAMO BIOSCIENCES, INC.","C12Q1/68","435/6.12 | 435/6.13","C12N15/1058 | C07K14/4702 | C12N15/102 | C12N15/1034 | C12N15/62 | C12N15/63 | C12N15/66 | C12N15/67 | C12Q1/6811 | G06F19/22 | C12Q1/6811 | C07K2319/00 | C07K2319/02 | C07K2319/09 | C07K2319/24 | C07K2319/43 | C07K2319/71 | C07K2319/75 | C07K2319/81 | G06F19/28 | C12Q2531/113 | C12Q2525/191 | C12Q2522/101","2","2","US7650351 | US9268903","20","US6090947 | US5585245 | US5766891 | US6444421 | US5935830 | US5436142 | US5500356 | US5866330 | US6013453 | US5422251 | US6007988 | US5635355 | US5501964 | US5998140 | US5789538 | US5176996 | US6023659 | US5525471 | US5695937 | US5958738"
"US7785792","Targeted modification of chromatin structure","Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences.","2008","2008-07-10","2010","2010-08-31","""A method of screening for a compound that modulates the activity of a chromatin modifying enzyme, the method comprising the steps of:(a) contacting an isolated cell with the compound, wherein the cell comprises a polynucleotide encoding fusion protein comprising a zinc finger protein and a functional chromatin modifying enzyme and wherein the ZFP binds to a gene within the cell; and(b) determining the level of expression of the gene, wherein a difference in gene expression between the contacted cells as compared to control cells is indicative that the compound modulates activity of the chromatin modifying enzyme.""","Alan P. Wolffe | Trevor N. Collingwood | Philip D. Gregory | Andrew Snowden | Fyodor Urnov","SANGAMO BIOSCIENCES, INC.","C12Q1/34 | C12N15/00 | C12Q1/66 | C12Q1/68","435/8 | 435/18 | 435/455 | 435/6.12 | 435/6.13","C12N15/1058 | C07K14/4702 | C12N15/102 | C12N15/1034 | C12N15/62 | C12N15/63 | C12N15/66 | C12N15/67 | C12Q1/6811 | G06F19/22 | C07K2319/00 | C07K2319/02 | C07K2319/09 | C07K2319/24 | C07K2319/43 | C07K2319/71 | C07K2319/75 | C07K2319/81 | G06F19/28","0","0",,"6","US6534261 | US6015709 | US6183965 | US6607882 | US5972608 | US6153383"
"US7888121","Methods and compositions for targeted cleavage and recombination","Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.","2004","2004-08-06","2011","2011-02-15","""A method for cleaving genomic cellular chromatin in a region of interest of an isolated cell, the method comprising:(a) selecting first and second nucleotide sequences in the region of interest;(b) engineering first and second zinc finger binding domains to bind to the first and second nucleotide sequences;(c) constitutively expressing a first fusion protein in a cell, the first fusion protein comprising the first engineered zinc finger binding domain and a first FokI cleavage half-domain;(d) constitutively expressing a second fusion protein in the cell, the second fusion protein comprising:(i) the second zinc finger binding domain; and(ii) a second Fold cleavage half-domain;wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain, the first fusion protein binds to the first nucleotide sequence, the second fusion protein binds to the second nucleotide sequence located between 2 and 50 nucleotides from the first nucleotide sequence, and the cellular chromatin is cleaved in the region of interest.""","Fyodor Urnov | Michael C. Holmes | Jeffrey C. Miller | Carl O. Pabo","SANGAMO BIOSCIENCES, INC.","C12N15/86 | C12N15/79 | C12N15/82 | C12N15/861 | C07H21/04 | C12N15/00 | C12N15/85","435/471 | 435/440 | 435/455 | 435/468 | 435/456 | 435/320.1 | 536/234 | 435/463 | 536/23.4","A61K35/12 | C07K14/43595 | C07K14/4717 | C07K14/715 | C12N9/14 | C12N9/22 | C12N15/62 | C12N15/85 | C07K2319/00 | C07K2319/09 | C07K2319/81 | C12N2800/80","23","23","US8980583 | US9222105 | US9670271 | US9650648 | US9057057 | US9574211 | US9522936 | US9567609 | US9523098 | US9717759 | US8771986 | US9376484 | US9394545 | US9249428 | US9624498 | US9629877 | US9616090 | US9161995 | US9816074 | US9701758 | US8895264 | US9150847 | US9255250","26","US6140081 | US4665184 | US5436150 | US6331658 | US5955341 | US5789155 | US6453242 | US6479626 | US6326166 | US5789538 | US6013453 | US6242568 | US5356802 | US6007988 | US4942227 | US6534261 | US6395523 | US6265196 | US5487994 | US5945577 | US4795700 | US6147276 | US5916794 | US5792640 | US6140466 | US6077710"
"US8110379","Targeted integration into the PPP1R12C locus","Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.","2008","2008-04-24","2012","2012-02-07","""A method for expressing at least one product of an exogenous nucleic acid sequence in an isolated cell, the method comprising:(a) expressing a first fusion protein in the cell, the first fusion protein comprising a first DNA-binding domain and a first cleavage domain or cleavage half-domain, wherein the first DNA-binding domain has been engineered to bind to a first target site in the PPP1R12C gene in the genome of the cell, wherein the DNA-binding domain is a zinc finger binding domain; and(b) contacting the cell with a polynucleotide comprising an exogenous nucleic acid sequence under conditions such that the first fusion protein cleaves the genome of the cell in the PPP1R12C gene and the exogenous nucleic acid sequence is inserted in a homology dependent manner into the cleavage site and expressed.""","Russell DeKelver | Philip D. Gregory | David Paschon | Phillip Y. Tam | Fyodor Urnov","SANGAMO BIOSCIENCES, INC.","C12P21/00 | C12N15/85","435/455 | 435/70.1","C12N15/907 | C07K14/435 | C07K14/43595 | C12N9/22 | C12N15/1082 | C12N15/113 | C12Y301/21004 | C07K2319/81 | C12N2800/10 | C12N2800/30","10","10","US9816074 | US9757420 | US9650648 | US9567609 | US9522936 | US9616090 | US9597357 | US9574211 | US9255250 | US9624498","15","US6200759 | US6410248 | US6479626 | US6534261 | US6140466 | US5436150 | US5789538 | US6007988 | US5356802 | US5925523 | US6013453 | US5487994 | US6242568 | US6140081 | US6453242"
"US8133733","Nonviral vectors for delivering polynucleotides to target tissues","Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal.","2007","2007-10-31","2012","2012-03-13","""A method for delivering a polynucleotide to one or more cells the method comprising:contacting the one or more cells with the polynucleotide packaged with a mitochondrial transcription factor A (TFAM) polypeptide fusion protein comprising a protein transduction domain, a cell-specific targeting signal and the TFAM polypeptide wherein the TFAM polypeptide comprises two HMG box domains and binds the polynucleotide.""","Shaharyar M. Khan","Genesia Corporation","C12Q1/68 | C07K14/435 | C12N15/00 | C07K14/00","530/350 | 530/300 | 435/468 | 530/388.21 | 435/455","C12N15/87 | A61K48/005 | A61K48/0058 | C12N15/62 | C12N15/85 | A61K48/00 | C07K2319/035 | C07K2319/07 | C07K2319/09 | C07K2319/10 | C07K2319/81 | C12N2810/40","8","8","US8470972 | US8952133 | US8541550 | US9334332 | US9540443 | US8507277 | US9605081 | US8927691","10","US6127159 | US6903077 | US6017734 | US6759574 | US6531647 | US5831020 | US7001768 | US6506559 | US6835810 | US5804445"
"US8313925","Zinc finger proteins and method for inactivating a dhfr gene in a chinese hamster ovary cell","Disclosed herein are methods and compositions for targeted integration of a exogenous sequence into a predetermined target site in a genome for use, for example, in protein expression and gene inactivation.","2009","2009-03-09","2012","2012-11-20","""A protein comprising an engineered zinc finger protein DNA-binding domain, wherein the DNA-binding domain comprises four zinc finger recognition regions ordered F1 to F4 from N-terminus to C-terminus, and wherein F1, F2, F3, and F4 comprise the following amino acid sequences:F1:QSGALAR(SEQ&#x2003;ID&#x2003;NO:&#x2003;229) F2:RSDNLRE(SEQ&#x2003;ID&#x2003;NO:&#x2003;230) F3:QSSDLSR(SEQ&#x2003;ID&#x2003;NO:&#x2003;231) F4:TSSNRKT.(SEQ&#x2003;ID&#x2003;NO:&#x2003;232)""","Philip D. Gregory | Jeffrey C. Miller","SANGAMO BIOSCIENCES, INC.","C07K19/00 | C07H21/04 | C12N15/62 | C12P21/00 | C12N15/00 | C12N5/16 | C07K14/00","530/350 | 435/358 | 536/232 | 536/234 | 435/455 | 435/69.1 | 536/23.2 | 536/23.4","C12N15/907 | A61K48/0008 | A61K48/005 | A61K48/0058 | C12N9/22 | C12N15/62 | C12N15/90 | C07K2319/00 | C07K2319/81","13","13","US9683033 | US9505833 | US9550826 | US9512214 | US9499614 | US9505834 | US9688752 | US9522953 | US9598667 | US9365645 | US9499616 | US9708400 | US9708399","48","US4797368 | US6410248 | US6933113 | US6453242 | US4485054 | US6506559 | US4217344 | US7008764 | US6824978 | US6458565 | US5061620 | US6479626 | US6242568 | US4186183 | US5681559 | US4946787 | US6528313 | US4501728 | US4837028 | US6645489 | US4603044 | US5420032 | US6667064 | US6335195 | US5173414 | US5585245 | US5176996 | US6528314 | US6534261 | US5789538 | US6140466 | US6007988 | US4261975 | US4897355 | US6013453 | US4774085 | US5049386 | US5928638 | US6140081 | US5422251 | US5925523 | US6200759 | US5356802 | US4235871 | US5436150 | US4957773 | US5487994 | US6395523"
"US8409861","Targeted deletion of cellular DNA sequences","Disclosed herein are methods and compositions for targeted deletion of double-stranded DNA. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, and polynucleotides encoding same. Methods for targeted deletion include introduction of such fusion proteins, or polynucleotides encoding same, into a cell such that two targeted cleavage events occur. Subsequent cellular repair mechanisms result in deletion of sequences between the two cleavage sites.","2005","2005-12-15","2013","2013-04-02","""A method for deleting sequences in a region of interest in double-stranded DNA of genomic cellular chromatin in a cell, the method comprising:expressing first, second, third and fourth fusion proteins in the cell, each of the fusion proteins comprising:(i) a zinc finger DNA-binding domain that binds to a target site in the DNA, and(ii) a FokI cleavage half-domain,wherein the cleavage half-domain of at least one of the fusion proteins comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain; andfurther wherein:(a) the first and second fusion proteins bind to first and second target sites respectively, wherein a first cleavage site lies between the first and second target sites, and(b) the third and fourth fusion proteins bind to third and fourth target sites respectively, wherein a second cleavage site lies between the third and fourth target sites;such that the first and second fusion proteins cleave the DNA at the first cleavage site, the third and fourth fusion proteins cleave the DNA at the second cleavage site, and DNA ends are rejoined such that sequences between the first and second cleavage sites are deleted.""","Dmitry M. Guschin | Michael C. Holmes","SANGAMO BIOSCIENCES, INC.","C12N15/90 | C12N15/00 | C12N15/87","435/455 | 435/440 | 435/471 | 435/468 | 435/463","C12N15/85 | C07K14/4702 | C12N9/22 | C12N15/10 | C07K2319/81","8","8","US9574211 | US9624498 | US9567609 | US9522936 | US9616090 | US9249428 | US9434776 | US9816074","26","US6077710 | US5792640 | US4942227 | US6140081 | US5356802 | US6534261 | US5955341 | US6242568 | US5945577 | US5789538 | US5948678 | US6326166 | US6147276 | US5487994 | US6479626 | US5916794 | US5436150 | US4795184 | US6007988 | US6265196 | US6331658 | US5789155 | US4665184 | US6140466 | US6013453 | US6453242"
"US8507277","Nonviral vectors for delivering polynucleotides","Methods and compositions for delivering polynucleotides are provided. One embodiment provides a non-viral vector comprising a recombinant polynucleotide-binding protein comprising a protein transduction domain operably linked to a targeting signal. Methods for modifying the genome of non-nuclear organelles are also provided.","2006","2006-03-24","2013","2013-08-13","""A method of compensating for a Leber's Hereditary Optic Neuropathy (LHON) mutation wherein the method comprises directly contacting an eye of a subject with the LHON mutation with a mitochondrial replicon comprising an expression regulatory element operably linked to the LHON wildtype mtDNA sequence and an effective amount of a non-viral vector to package the replicon wherein the non-viral vector comprises a protein transduction domain, a mitochondrial localization signal, and mature transcription factor A, mitochondrial (TFAM).""","Shaharyar M. Khan","Genesia Corporation","A61K48/00 | C12N15/00 | A61K47/00","514/44 | 530/350 | 530/300 | 530/388.21 | 435/455 | 514/44R","A61K48/005 | A61K48/0058 | C12N15/62 | C12N15/85 | C07K2319/07 | C07K2319/09 | C07K2319/10 | C07K2319/81","0","0",,"226","US7459145 | US7001768 | US4622302 | US7250299 | US8103278 | US7795380 | US7306944 | US6248532 | US7319086 | US6054312 | US6246427 | US5728399 | US7750134 | US7666668 | US7741453 | US7981669 | US6835810 | US6878374 | US6143564 | US6372720 | US5859310 | US6063565 | US7709621 | US7553667 | US6120797 | US5981273 | US6207648 | US6734171 | US5804445 | US6849272 | US6951756 | US7042608 | US6099847 | US7393478 | US7456272 | US7371922 | US6495346 | US7273722 | US5914231 | US7060461 | US5837533 | US6632800 | US4873089 | US7645865 | US5885613 | US6770632 | US5799515 | US5866755 | US5422277 | US6914124 | US6337070 | US5166898 | US6127159 | US6759518 | US7993656 | US7655413 | US5908777 | US6506559 | US7220576 | US7056529 | US7655393 | US6221665 | US7687611 | US6004941 | US7202227 | US4952496 | US7608271 | US5789156 | US6407178 | US6251640 | US6252136 | US6312727 | US5723319 | US7820624 | US5650298 | US6586411 | US5149782 | US6136954 | US6903077 | US8052979 | US6875448 | US6323391 | US6458026 | US7566454 | US6242667 | US7455988 | US7879813 | US6271348 | US6986902 | US7993826 | US6093537 | US4901269 | US8034910 | US5733540 | US7910364 | US7741431 | US6872406 | US6531647 | US6294363 | US7579515 | US6759574 | US6731187 | US6633933 | US5766626 | US7838637 | US6737506 | US7811803 | US5948681 | US8110545 | US5693489 | US7144994 | US6867036 | US6022735 | US6004808 | US6544780 | US7807363 | US7048925 | US7575896 | US5552155 | US5922927 | US6897196 | US6416997 | US7666868 | US6297004 | US5709879 | US6271341 | US5968773 | US7393541 | US6696038 | US5756041 | US8062891 | US7541446 | US7973019 | US8114581 | US7273620 | US8124843 | US6087166 | US7999073 | US6255071 | US6759236 | US8133733 | US5770414 | US5831020 | US5916803 | US6379965 | US8007786 | US7376128 | US6444871 | US7881468 | US6210708 | US7638608 | US6200956 | US7060291 | US5985318 | US8088747 | US7256043 | US7744896 | US7671253 | US5869320 | US5985573 | US5814618 | US6210717 | US5766902 | US7829104 | US7244435 | US6025192 | US6274322 | US6294191 | US7829290 | US7410729 | US7704969 | US6270761 | US7041312 | US7090837 | US5912411 | US7727538 | US6358524 | US7521415 | US7402409 | US6037348 | US5888981 | US8053552 | US7329807 | US7842460 | US7582301 | US6113946 | US5789230 | US6967197 | US5945400 | US6780639 | US6410057 | US5780444 | US7964571 | US6306625 | US6783756 | US5792645 | US6771623 | US5851796 | US5547932 | US7803617 | US7498165 | US6743781 | US7982022 | US6017734 | US6500800 | US7018819 | US5589362 | US4803072 | US6652886 | US6136536 | US7919075 | US6511676 | US6267987 | US5654168 | US6077663 | US8039587 | US7524648 | US6692911 | US5464758 | US6080791 | US6251365 | US8071110 | US7989185 | US6972650 | US6127170 | US4752473"
"US8524500","Methods and compositions for targeted cleavage and recombination","Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.","2010","2010-07-16","2013","2013-09-03","""A method of targeted mutation of a non-coding sequence in a region of interest in cellular chromatin in an isolated plant or mammalian cell containing a region of interest in cellular chromatin, the method comprising:(a) selecting first and second nucleotide sequences in the region of interest;(b) engineering first and second zinc finger binding domains to bind to the first and second nucleotide sequences;(c) expressing a first fusion protein in the isolated cell, the first fusion protein comprising the first engineered zinc finger binding domain and a first FokI cleavage half-domain; and(d) expressing a second fusion protein in the cell, the second fusion protein comprising the second zinc finger binding domain and a second FokI cleavage half-domainwherein the first and second fusion proteins cleave cellular chromatin and mutate the non-coding sequence in the region of interest and further wherein one of the cleavage half-domains comprises an alteration in amino acid 490 of the wild-type dimerization interface of the cleavage half-domain.""","Fyodor Urnov | Michael C. Holmes | Jeffrey C. Miller | Carl O. Pabo","SANGAMO BIOSCIENCES, INC.","C12N15/87 | C12N15/00","435/468 | 435/455 | 435/440 | 435/463","A61K35/12 | C07K14/43595 | C07K14/4717 | C07K14/715 | C12N9/14 | C12N9/22 | C12N15/62 | C12N15/85 | C07K2319/00 | C07K2319/09 | C07K2319/81 | C12N2800/80","0","0",,"30","US6750378 | US6140466 | US5436150 | US5955341 | US6534261 | US5714352 | US5945577 | US6077710 | US6576443 | US6453242 | US4665184 | US6140081 | US6395523 | US5356802 | US5916794 | US5487994 | US4942227 | US6265196 | US6007988 | US4795184 | US6242568 | US6331658 | US5464764 | US5792640 | US6013453 | US5789538 | US6326166 | US5789155 | US6479626 | US6147276"
"US8597912","Methods and compositions for generation of Bax-and Bak-deficient cell lines","Disclosed herein are methods and compositions for generation of Bak- and/or Bax-deficient cell lines using engineered nucleases.","2009","2009-06-10","2013","2013-12-03","""A protein comprising an engineered zinc finger protein DNA-binding domain that specifically binds to a target site in a Bak or Bax gene, wherein the DNA-binding domain comprises four, five or six zinc finger recognition regions, ordered F1 to F4 for proteins with four zinc finger domains, ordered F1 to F5 for proteins with five zinc finger domains and ordered F1 to F6 for proteins with six zinc finger domains from N-terminus to C-terminus, and further wherein the zinc finger proteins is selected from the group consisting of a protein comprising the following amino acid sequences in the zinc finger recognition regions:(i) F1: RSDHLTT (SEQ ID NO:9);F2: RSDHLSE (SEQ ID NO:10);F3: RNDNRKT (SEQ ID NO:11);F4: QSGHLQR (SEQ ID NO:12); andF5: QSGHLSR (SEQ ID NO:13) and wherein the protein binds to the target sequence shown in SEQ ID NO:23;(ii) F1: RSDSLSA (SEQ ID NO:14);F2: DRSSRTK (SEQ ID NO:15);F3: RSDDLTR (SEQ ID NO:16); andF4: RSDALAR (SEQ ID NO:17) and wherein the protein binds to the target sequence shown in SEQ ID NO:24;(iii) F1: DRSHLSR (SEQ ID NO:34);F2: TSGSLTR (SEQ ID NO:35);F3: RSDSLSA (SEQ ID NO:14);F4: DRSSRTK (SEQ ID NO:15);F5: RSDNLSE (SEQ ID NO:36); andF6: HSNARKT (SEQ ID NO:37); and wherein the protein binds to the target sequence shown in SEQ ID NO:33;(iv) F1: RSDNLSV (SEQ ID NO:39);F2: DRSNLTR (SEQ ID NO:40);F3: RSDTLSE (SEQ ID NO:41); andF4: RSQTRKT (SEQ ID NO:42); and wherein the protein binds to the target sequence shown in SEQ ID NO:38;(v) F1: QNAHRKT (SEQ ID NO:50);F2: QSGDLTR (SEQ ID NO: 53);F3: QSGDLTR (SEQ ID NO:53);F4: QSSNLAR (SEQ ID NO:54); andF5: TSSNRKT (SEQ ID NO: 55); and wherein the protein binds to the target sequence shown in SEQ ID NO:52;(vi) F1: RSDNLAR (SEQ ID NO:57);F2: QSGDLTR (SEQ ID NO: 53);F3: DNRQLIT (SEQ ID NO:58);F4: TSSNLSR (SEQ ID NO:8);F5: RSDTLSR (SEQ ID NO:59); andF6: RNDDRIT (SEQ ID NO:60); and wherein the protein binds to the target sequence shown in SEQ ID NO:56;(vii) F1: RSDNLTT (SEQ ID NO:62);F2: RSDHLSR (SEQ ID NO:63);F3: QSSDLRR (SEQ ID NO:64);F4: QSSHLTR (SEQ ID NO:3); andF5: RSDHLTQ (SEQ ID NO:65); and wherein the protein binds to the target sequence shown in SEQ ID NO:61;(viii) F1: QSGSLTR (SEQ ID NO:67);F2: TSSNRKT (SEQ ID NO:55);F3: DRSHLTR (SEQ ID NO:68);F4: RSDDRKT (SEQ ID NO:69);F5: NRTDLIR (SEQ ID NO:7); andF6: TSSNLSR (SEQ ID NO:8); and wherein the protein binds to the target sequence shown in SEQ ID NO:66;(ix) F1: RSDHLST (SEQ ID NO:1);F2: DRSHLAR (SEQ ID NO:2);F3: QSSHLTR (SEQ ID NO:3); andF4: RSDNLRE (SEQ ID NO:4); and wherein the protein binds to the target sequence shown in SEQ ID NO:1;(x) F1: RSANLSV (SEQ ID NO:5);F2: DRANLSR (SEQ ID NO:6);F3: NRTDLIR (SEQ ID NO:7); andF4: TSSNLSR (SEQ ID NO:8); and wherein the protein binds to the target sequence shown in SEQ ID NO:22;(xi) F1: DRSDLSR (SEQ ID NO:45);F2: NRTDLIR (SEQ ID NO:7);F3: TSSNLSR (SEQ ID NO:8);F4: RSDTLSQ (SEQ ID NO:46); andF5: DRSARTR (SEQ ID NO:47); and wherein the protein binds to the target sequence shown in SEQ ID NO:44; and(xii) F1: RSDALSV (SEQ ID NO:48);F2: DSSHRTR (SEQ ID NO:49);F3: QNAHRKT (SEQ ID NO:50);F4: RSDHLST (SEQ ID NO:1); andF5: TSGHLSR (SEQ ID NO:51) and wherein the protein binds to the target sequence shown in SEQ ID NO:44.""","Trevor N. Collingwood | Philip D. Gregory","SANGAMO BIOSCIENCES, INC.","C12P21/00 | C12N15/00","435/455 | 435/440 | 435/252.3 | 530/350 | 435/69.7","C12N5/0018 | C12N9/22 | C07K2319/81 | C12N2501/48 | C12N2510/02","0","0",,"26","US5356802 | US6479626 | US6140466 | US6599692 | US5487994 | US7163824 | US6824978 | US6689558 | US6410248 | US5789538 | US6242568 | US6453242 | US6140081 | US6013453 | US6503717 | US6979539 | US7013219 | US6200759 | US7153949 | US6607882 | US6007988 | US6534261 | US5436150 | US6903185 | US5925523 | US6933113"
"US8771985","Genome editing of a ","Disclosed herein are methods and compositions for genome editing of a <i>Rosa </i>locus, using fusion proteins comprising a zinc-finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding said fusion proteins are also provided, as are cells comprising said polynucleotides and fusion proteins.","2011","2011-04-25","2014","2014-07-08","""An isolated fusion protein comprising a nuclease domain and an engineered zinc finger DNA-binding domain, wherein the engineered zinc finger DNA-binding domain binds to a target site in a rat Rosa gene and the engineered zinc finger DNA-binding domain comprises four, five or six zinc finger DNA recognition regions designated and ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus and further wherein the engineered zinc finger DNA-binding domain comprises the zinc finger DNA recognition regions selected from the group consisting of:(i) F1: DRSDLSR (SEQ ID NO:38);F2: RSDDLTR (SEQ ID NO:39);F3: TSGHLSR (SEQ ID NO:40);F4: RSDNLSV (SEQ ID NO:41); andF5: RSANLTR (SEQ ID NO:42);(ii) F1: QSDHLTK (SEQ ID NO:43);F2: NSSNLSR (SEQ ID NO:44);F3: RSDHLTK (SEQ ID NO:45);F4: NSDHLSR (SEQ ID NO:46); andF5: RSDHLSR (SEQ ID NO:47);(iii) F1: RSDHLSE (SEQ ID NO:48);F2: RSAALAR (SEQ ID NO:49);F3: RSDHLST (SEQ ID NO:50);F4: QNAHRIT (SEQ ID NO:51); andF5: RSAVLSE (SEQ ID NO:52);(iv) F1: QSGDLTR (SEQ ID NO:17);F2: TSGSLTR (SEQ ID NO: 18);F3: RSANLTR (SEQ ID NO:42);F4: RSDHLTK (SEQ ID NO:45); andF5: NSDHLSR (SEQ ID NO:46);(v) F1: RSANLTR(SEQ ID NO:42);F2: QSGDLTR (SEQ ID NO: 17);F3: QSGDLTR (SEQ ID NO: 17);F4: RSANLAR (SEQ ID NO:53); andF5: RSDNLRE (SEQ ID NO:54);(vi) F1: RSDHLST (SEQ ID NO:50);F2: DNRDRIK (SEQ ID NO:55);F3: RSDTLSE (SEQ ID NO:56);F4: QSSHLAR (SEQ ID NO:57); andF5: QNAHRKT (SEQ ID NO:22);(vii) F1: QSGDLTR (SEQ ID NO:17);F2: QSGDLTR (SEQ ID NO: 17);F3: RSDNLTR (SEQ ID NO:58);F4: RSDNLSE (SEQ ID NO:21); andF5: QNAHRKT (SEQ ID NO:22);(viii) F1: DRSDLSR (SEQ ID NO:38);F2: RSDHLST (SEQ ID NO:50);F3: DNRDRIK (SEQ ID NO:55);F4: RSDTLSE (SEQ ID NO:56); andF5: QSSHLAR (SEQ ID NO:57);(ix) F1: QSGDLTR (SEQ ID NO:17);F2: RSDNLTR (SEQ ID NO:58);F3: RSDNLSE (SEQ ID NO:21);F4: QNAHRKT (SEQ ID NO:22);F5: RSDHLSE (SEQ ID NO:48); andF6: TSSTRKT (SEQ ID NO:59);(x) F1: TSGNLTR(SEQ ID NO:60);F2: QSGNLAR (SEQ ID No:61);F3: RSDALSV (SEQ ID NO:62);F4: DSSHRTR (SEQ ID NO:63); andF5: RSDVLSE (SEQ ID NO:64)(xi) F1: RSDNLSE (SEQ ID NO:21);F2: QNAHRKT (SEQ ID NO:22);F3: RSDHLSE (SEQ ID NO:48);F4: TSSTRKT (SEQ ID NO:59); andF5: TSGHLSR (SEQ ID NO:40);(xii) F1: TSGNLTR (SEQ ID NO:60);F2: QSGNLAR (SEQ ID NO:61);F3: RSDALSV (SEQ ID NO:62); andF4: DSSHRTR (SEQ ID NO:63);(xiii) F1: QRSNLVR (SEQ ID NO:65);F2: RSDHLTQ (SEQ ID NO:66);F3: QSGHLQR (SEQ ID NO:67); andF4: DRSHLAR (SEQ ID NO:68);(xiv) F1: RSDVLSE (SEQ ID NO:64);F2: QRNHRTT (SEQ ID NO:69);F3: TKRSLIE (SEQ ID NO:70);F4: TSSNLSR (SEQ ID NO:71);F5: RSDDLSK (SEQ ID NO:25); andF6: DNRDRIK (SEQ ID NO:55);(xv) F1: RSDHLSA (SEQ ID NO:72);F2: QSGHLSR (SEQ ID NO:24);F3: RSDHLSR (SEQ ID NO:47);F4: QNDNRIK (SEQ ID NO:73); andF5: QSGNLAR (SEQ ID NO:61);(xvi) F1: NNRDLIN (SEQ ID NO:74);F2: TSSNLSR (SEQ ID NO:71);F3: RSDVLSE (SEQ ID NO:64);F4: QRNHRTT (SEQ ID NO:69);F5: TKRSLIE (SEQ ID NO:70); andF6: TSSNLSR (SEQ ID NO:71).""","Xiaoxia Cui | Gregory D. Davis | Philip D. Gregory | Michael C. Holmes | Edward J. Weinstein","SANGAMO BIOSCIENCES, INC. | Sigma-Aldvich Co. LLC","C07K14/00 | C07K1/00 | C07K17/00 | C12P21/06 | C12N5/07 | C07H21/04 | C12N15/00 | C12N5/10","536/234 | 435/455 | 536/232 | 530/350 | 435/196 | 435/352 | 435/69.1 | 536/23.2 | 536/23.4","C12N9/22 | A01K67/0275 | C12N15/102 | C12N15/907 | A01K2207/05 | A01K2217/07 | A01K2227/105 | A01K2267/03 | A61K38/00 | C07K2319/81","0","0",,"26","US6007988 | US7153949 | US5487994 | US6534261 | US6200759 | US5925523 | US5436150 | US5356802 | US6689558 | US6933113 | US7163824 | US6903185 | US6013453 | US6140081 | US6503717 | US6479626 | US6607882 | US6824978 | US6140466 | US6979539 | US7013219 | US5789538 | US6410248 | US6242568 | US6599692 | US6453242"
"US8822221","Targeted integration into the PPP1R12C locus","Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.","2011","2011-12-30","2014","2014-09-02","""A method for expressing at least one product of an exogenous nucleic acid sequence in an isolated stem cell, the method comprising:(a) expressing a first fusion protein in the cell, the first fusion protein comprising a first zinc finger DNA-binding domain and a first cleavage domain or cleavage half-domain, wherein the first DNA-binding domain has been engineered to bind to a first target site in the PPP1R12C gene in the genome of the stem cell; and(b) contacting the cell with a polynucleotide comprising an exogenous nucleic acid sequence under conditions such that the first fusion protein cleaves the genome of the cell in the PPP1R12C gene and the exogenous nucleic acid sequence is inserted in a homology dependent manner into the cleavage site and expressed.""","Russell DeKelver | Philip D. Gregory | David Paschon | Phillip Y. Tam | Fyodor Urnov","SANGAMO BIOSCIENCES, INC.","C12N15/10 | C12N15/85","435/325 | 435/455","C12N15/907 | C07K14/435 | C07K14/43595 | C12N9/22 | C12N15/1082 | C12N15/113 | C12Y301/21004 | C07K2319/81 | C12N2800/10 | C12N2800/30","0","0",,"15","US6242568 | US5356802 | US6410248 | US6534261 | US6140081 | US6007988 | US6479626 | US6013453 | US5436150 | US5789538 | US6200759 | US6453242 | US5925523 | US5487994 | US6140466"
"US8871905","Modification of CXCR4 using engineered zinc finger proteins","Disclosed herein are methods and compositions for modulating activity of CXCR4 genes, for example using zinc finger transcription factors (ZF-TFs) or zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZF-TFs or ZFNs, vectors comprising polynucleotides encoding ZF-TFs or ZFNs and cells comprising polynucleotides encoding ZF-TFs or ZFNs and/or cells comprising ZF-TF or ZFNs are also provided.","2010","2010-03-18","2014","2014-10-28","""A zinc finger protein comprising 4 zinc finger DNA-binding domains, wherein(i) each zinc finger DNA-binding domain binds to a 3 base pair target subsite;(ii) the zinc finger protein binds to a target site in a CXCR4 gene; and(iii) the target site is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:11, SEQ ID NO:16, SEQ ID NO:21 and SEQ ID NO:25.""","Michael C. Holmes | Jeffrey C. Miller | Jianbin Wang","SANGAMO BIOSCIENCES, INC.","C07K14/705 | A61K38/00 | C07K14/715 | C12N15/62 | C12N15/00","536/234 | 424/941 | 514/44 | 435/462 | 424/932 | 435/455 | 530/350 | 424/93.2 | 424/94.1 | 536/23.4","A61K35/17 | C07K14/70596 | C07K14/7158 | A61K48/00 | C07K2319/81","1","1","US9267153","21","US6140466 | US5487994 | US6410248 | US6140081 | US6824978 | US5789538 | US5925523 | US6013453 | US6534261 | US6607882 | US6200759 | US6007988 | US6453242 | US6503717 | US6599692 | US6242568 | US6979539 | US6933113 | US5356802 | US7013219 | US7163824"
"US8895264","Methods and compositions for modification of the ","Nucleases and methods of using these nucleases for modification of an HPRT locus and for increasing the frequency of gene modification at a targeted locus and clones and for generating animals.","2012","2012-10-25","2014","2014-11-25","""A non-naturally occurring fusion protein comprising a transcription activator like effector domain DNA binding protein (TALE) that binds to a target site in an endogenous hypoxanthine guanine phosphoribosyltransferase (HPRT) gene comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:69-78 and a nuclease cleavage domain, wherein the TALE domain comprises a repeat variable diresidue (RVD) sequence in the order presented and selected from a single row of Table 4.""","Gregory J. Cost | Michael C. Holmes | Noriyuki Kasahara | Josee Laganiere | Jeffrey C. Miller | David Paschon | Edward J. Rebar | Fyodor Urnov | Lei Hu Zhang","The Regents of the University of California | SANGAMO BIOSCIENCES, INC.","C12N15/85 | C12N15/00 | C07H21/04 | C07K1/00 | C12Q1/68 | C12N15/86 | C12N15/90 | C12N9/10 | C12N9/96 | C12N5/071","435/366 | 435/455 | 435/372.2 | 435/372.3 | 536/234 | 530/350 | 435/456 | 435/69.1 | 536/23.4","C12N15/85 | C12N9/1077 | C12N9/22 | C12N9/96 | C12N15/907 | C12Y204/02008 | C12Y301/21004 | C07K2319/81","0","0",,"35","US7153949 | US6007988 | US6933113 | US6200759 | US5356802 | US6503717 | US5789538 | US5436150 | US7951925 | US6599692 | US6824978 | US7030215 | US7262054 | US7067317 | US7013219 | US6979539 | US6903185 | US7070934 | US7163824 | US6453242 | US7253273 | US6479626 | US5487994 | US6242568 | US6794136 | US7888121 | US6140081 | US6607882 | US6534261 | US6689558 | US5925523 | US6410248 | US7361635 | US6140466 | US6013453"
"US8945868","Methods and compositions for modification of a HLA locus","Disclosed herein are methods and compositions for modulating the expression of a HLA locus or for selectively deleting or manipulating a HLA locus or HLA regulator.","2011","2011-07-21","2015","2015-02-03","""A protein comprising an engineered zinc finger DNA-binding domain, wherein the engineered zinc finger DNA-binding domain comprises four, five or six zinc finger DNA recognition regions designated and ordered F1 to F4, F1 to F5 or F1 to F6 from N-terminus to C-terminus and further wherein the engineered zinc finger DNA-binding domain comprises the zinc finger DNA recognition regions selected from the group consisting of:(i) F1: QSSHLTR (SEQ ID NO:1);F2: RSDHLTT (SEQ ID NO:2);F3: RSDTLSQ (SEQ ID NO:3);F4: RSADLSR (SEQ ID NO:4);F5: QSSDLSR (SEQ ID NO:5); andF6: RSDALTQ (SEQ ID NO:6), wherein the protein binds to the target site set forth in SEQ ID NO:97 in an endogenous human leukocyte antigen (HLA) A2 gene;(ii) F1: QKTHLAK (SEQ ID NO:7);F2: RSDTLSN (SEQ ID NO:8);F3: RKDVRIT (SEQ ID NO:9);F4: RSDHLST (SEQ ID NO:10); andF5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:98 in an endogenous HLA A2 gene;(iii) F1: QNAHRKT (SEQ ID NO:12);F2: RSDSLLR (SEQ ID NO:13);F3: RNDDRKK (SEQ ID NO:14);F4: RSDHLST (SEQ ID NO:10); andF5: DSSARKK (SEQ ID NO:11), wherein the protein binds to the target site set forth in SEQ ID NO:99 in an endogenous HLA A2 gene;(iv) F1: DRSHLSR (SEQ ID NO:15);F2: RSDDLTR (SEQ ID NO:16);F3: DRSDLSR (SEQ ID NO:17); andF4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:100 in an endogenous HLA A3 gene;(v) F1: DRSALSR (SEQ ID NO:19);F2: QSSDLRR (SEQ ID NO:20);F3: DRSALSR (SEQ ID NO:19);F4: DRSHLAR (SEQ ID NO:21);F5: RSDDLSK (SEQ ID NO:22); andF6: DRSHLAR (SEQ ID NO:21), wherein the protein binds to the target site set forth in SEQ ID NO:101 in an endogenous HLA A3 gene;(vi) F1: SSELLNE (SEQ ID NO:23);F2: TSSHLSR (SEQ ID NO:24);F3: QSGDRNK (SEQ ID NO:25);F4: RSANLAR (SEQ ID NO:26); andF5: RSDNLRE (SEQ ID NO:27), wherein the protein binds to the target site set forth in SEQ ID NO:102 in an endogenous HLA B gene;(vii) F1: QSGDLTR (SEQ ID NO:28);F2: RSDDLTR (SEQ ID NO:16);F3: DQSTLRN (SEQ ID NO:29);F4: DRSNLSR (SEQ ID NO:30); andF5: DAFTRTR (SEQ ID NO:31), wherein the protein binds to the target site set forth in SEQ ID NO:103 in an endogenous HLA B gene;(viii) F1: RSDNLSE (SEQ ID NO:32);F2: ASKTRKN (SEQ ID NO:33);F3: TSGNLTR (SEQ ID NO:34); andF4: RSDALAR (SEQ ID NO:35), wherein the protein binds to the target site set forth in SEQ ID NO:104 in an endogenous HLA B gene;(ix) F1: DRSALSR (SEQ ID NO:19);F2: QSGNLAR (SEQ ID NO:36);F3: DRSALSR (SEQ ID NO:19);F4: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:105 in an endogenous HLA B gene;(x) F1: RSDNLSE (SEQ ID NO:32);F2: ASKTRKN (SEQ ID NO:33);F3: QSGHLSR (SEQ ID NO:18);F4: TSGHLSR (SEQ ID NO:37); andF5: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:106 in an endogenous HLA B gene;(xi) F1: RSADLTR (SEQ ID NO:38);F2: QSGDLTR (SEQ ID NO:28);F3: QSGNLAR (SEQ ID NO:36); andF4: QSGDLTR (SEQ ID NO:28), wherein the protein binds to the target site set forth in SEQ ID NO:107 in an endogenous HLA B gene;(xii) F1: QSGHLSR (SEQ ID NO:18);F2: RSDHLST (SEQ ID NO:10);F3: QSADRTK (SEQ ID NO:39);F4: TSGSLSR (SEQ ID NO:40); andF5: QSADRTK (SEQ ID NO:39), wherein the protein binds to the target site set forth in SEQ ID NO:108 in an endogenous HLA C gene;(xiii) F1: QSGDLTR (SEQ ID NO:28);F2: RSDHLST (SEQ ID NO:10);F3: QSADRTK (SEQ ID NO:39);F4: RSDNLSA (SEQ ID NO:41); andF5: RSDNRTT (SEQ ID NO:42), wherein the protein binds to the target site set forth in SEQ ID NO:109 in an endogenous HLA C gene;(xiv) F1: QRSNLVR (SEQ ID NO:43);F2: DRSALAR (SEQ ID NO:44);F3: QSSDLRR (SEQ ID NO:20);F4: RSDDLTR (SEQ ID NO:16); andF5: RSDDLTR (SEQ ID NO:16), wherein the protein binds to the target site set forth in SEQ ID NO:110 in an endogenous HLA C gene;(xv) F1: RSDDLTR (SEQ ID NO:16);F2: DRSDLSR (SEQ ID NO:17);F3: QSGHLSR (SEQ ID NO:18);F4: RSDHLSA (SEQ ID NO:45); andF5: ESRYLMV (SEQ ID NO:46), wherein the protein binds to the target site set forth in SEQ ID NO:111 in an endogenous HLA C gene;(xvi) F1: RSDHLST (SEQ ID NO:10);F2: DNANRTK (SEQ ID NO:47);F3: QSGDLTR (SEQ ID NO:28);F4: RSDALST (SEQ ID NO:48); andF5: ASSNRKT (SEQ ID NO:49), wherein the protein binds to the target site set forth in SEQ ID NO:112 in an endogenous DBP2 gene;(xvii) F1: TSGNLTR (SEQ ID NO:34);F2: DRSDLSR (SEQ ID NO:17);F3: RSDNLSE (SEQ ID NO:32);F4: RSANLTR (SEQ ID NO:50); andF5: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:113 in an endogenous DBP2 gene;(xviii) F1: RSDNLSE (SEQ ID NO:32);F2: TSGSLTR (SEQ ID NO:51);F3: TSGHLSR (SEQ ID NO:37);F4: RSDNLSQ (SEQ ID NO:52); andF5: ASNDRKK (SEQ ID NO:53), wherein the protein binds to the target site set forth in SEQ ID NO:114 in an endogenous DRA gene;(xix) F1: RSDNLSR (SEQ ID NO:54);F2: DNNARIN (SEQ ID NO:55);F3: RSDSLSV (SEQ ID NO:56);F4: QNQHRIN (SEQ ID NO:57); andF5: RSDHLSR (SEQ ID NO:58), wherein the protein binds to the target site set forth in SEQ ID NO:115 in an endogenous DRA gene;(xx) F1: DSSDRKK (SEQ ID NO:59);F2: DRSHLTR (SEQ ID NO:60);F3: RSDALAR (SEQ ID NO:35);F4: QSSDLSR (SEQ ID NO:5); andF5: RSDNLTT (SEQ ID NO:61), wherein the protein binds to the target site set forth in SEQ ID NO:116 in an endogenous transporter associated with antigen processing 1 (TAP1) gene;(xxi) F1: RSANLAR (SEQ ID NO:26);F2: QSGHLSR (SEQ ID NO:18);F3: TSGNLTR (SEQ ID NO:34);F4: QSGALVI (SEQ ID NO:62);F5: RSDHLSE (SEQ ID NO:63); andF6: RKHDRTK (SEQ ID NO:64), wherein the protein binds to the target site set forth in SEQ ID NO:117 in an endogenous TAP1 gene;(xxii) F1: QSSDLSR (SEQ ID NO:5);F2: QSGDLTR (SEQ ID NO:28);F3: QSSHLTR (SEQ ID NO:1):F4: RSDDRKT (SEQ ID NO:65);F5: TSGNLTR (SEQ ID NO:34); andF6: RSDDLTR (SEQ ID NO:16), wherein the protein binds to the target site set forth in SEQ ID NO:118 in an endogenous transporter associated with antigen processing 2(TAP2) gene;(xxiii) F1: RSDNLST (SEQ ID NO:66);F2: RSDALAR (SEQ ID NO:35);F3: RSDVLSA (SEQ ID NO:67);F4: DRSNRIK (SEQ ID NO:68);F5: RREDLIT (SEQ ID NO:69); andF6: TSSNLSR (SEQ ID NO:70), wherein the protein binds to the target site set forth in SEQ ID NO:119 in an endogenous TAP2 gene;(xxiv) F1: RSDNLSE (SEQ ID NO:32);F2: KRCNLRC (SEQ ID NO:71);F3: DRSDLSR (SEQ ID NO:17);F4: QTTHRNR (SEQ ID NO:72);F5: DRSDLSR (SEQ ID NO:17), andF6: QSSTRAR (SEQ ID NO:73), wherein the protein binds to the target site set forth in SEQ ID NO:120 in an endogenous tapasin gene;(xxv) F1: QSSDLR (SEQ ID NO:5);F2: RSDNLTR (SEQ ID NO:74);F3: QSSHLTR (SEQ ID NO:1);F4: QSSDLTR (SEQ ID NO:75);F5: RSDNLAR (SEQ ID NO:76); andF6: QKVNLMS (SEQ ID NO:77), wherein the protein binds to the target site set forth in SEQ ID NO:121 in an endogenous tapasin gene;(xxvi) F1: TSGNLTR (SEQ ID NO:34);F2: LSQDLNR (SEQ ID NO:78);F3: RSDSLSA (SEQ ID NO:79);F4: DRSHLAR (SEQ ID NO:21);F5: RSDHLST (SEQ ID NO:10); andF6: QSGHLSR (SEQ ID NO:18), wherein the protein binds to the target site set forth in SEQ ID NO:122 in an endogenous tapasin gene;(xxvii) F1: RSDDLTR (SEQ ID NO:16);F2: SSSNLTK (SEQ ID NO:80);F3: TSGSLSR (SEQ ID NO:40);F4: QSGDLTR (SEQ ID NO:28);F5: RSDHLSE (SEQ ID NO:63); andF6: RNRDRIT (SEQ ID NO:81), wherein the protein binds to the target site set forth in SEQ ID NO:123 in an endogenous tapasin gene;(xxviii) F1: RSDDLTR (SEQ ID NO:16);F2: RSDHLSE (SEQ ID NO:63);F3: NSRNRKT (SEQ ID NO:82);F4: RSDNLSQ (SEQ ID NO:52); andF5: ASNDRKK (SEQ ID NO:53), wherein the protein binds to the target site set forth in SEQ ID NO:124 in an endogenous class 2 transactivator (CTIIA) gene;(xxvix) F1: RSDDLSR (SEQ ID NO:83);F2: RNDDRKK (SEQ ID NO:14);F3: DRSDLSR (SEQ ID NO:17);F4: RSDHLSE (SEQ ID NO:63); andF5: ARSTRTN (SEQ ID NO:84), wherein the protein binds to the target site set forth in SEQ ID NO:125 in an endogenous CTIIIA gene;(xxx) F1: TSGNLTR (SEQ ID NO:34);F2: QSGNLAR (SEQ ID NO:36);F3: RSDHLTQ (SEQ ID NO:85);F4: ASMALNE (SEQ ID NO:86); andF5: TSSNLSR (SEQ ID NO:70), wherein the protein binds to the target site set forth in SEQ ID NO:126 in an endogenous regulatory factor X protein 5 (RXF5) gene;(xxxi) F1: RSDVLSE (SEQ ID NO:87);F2: RNQHRKT (SEQ ID NO:88);F3: RSDHLST (SEQ ID NO:10);F4: QSSDLRR (SEQ ID NO:20);F5: RSDNLST (SEQ ID NO:66); andF6: RSADRKN (SEQ ID NO:89), wherein the protein binds to the target site set forth in SEQ ID NO:127 in an endogenous RXF5 gene;(xxxii) F1: QSGDLTR (SEQ ID NO:28);F2: QWGTRYR (SEQ ID NO:90);F3: ERGTLAR (SEQ ID NO:91);F4: RSDNLRE (SEQ ID NO:27);F5: QSGDLTR (SEQ ID NO:28); andF6: TSGSLTR (SEQ ID NO:51), wherein the protein binds to the target site set forth in SEQ ID NO:128 in an endogenous T-cell receptor alpha (TRAC) gene;(xxxiii) F1: QSGDLTR (SEQ ID NO:28);F2: WRSSLAS (SEQ ID NO:92);F3: QSGDLTR (SEQ ID NO:28);F4: HKWVLRQ (SEQ ID NO:93); andF5: DRSNLTR (SEQ ID NO:94), wherein the protein binds to the target site set forth in SEQ ID NO:129 in an endogenous TRAC gene;(xxxiv)F1: RSDVLSA (SEQ ID NO:67);F2: DRSNRIK (SEQ ID NO:68);F3: RSDVLSE (SEQ ID NO:87);F4: QSGNLAR (SEQ ID NO:36); andF5: QSGSLTR (SEQ ID NO:95), wherein the protein binds to the target site set forth in SEQ ID NO:130 in an endogenous T-cell receptor beta (TRBC) gene; and(xxxv) F1: RSDHLST (SEQ ID NO:10);F2: RSDNLTR (SEQ ID NO:74);F3: DRSNLSR (SEQ ID NO:30);F4: TSSNRKT (SEQ ID NO:96);F5: RSANLAR (SEQ ID NO:26); andF6: RNDDRKK (SEQ ID NO:14), wherein the protein binds to the target site set forth in SEQ ID NO:131 in an endogenous TRBC gene.""","Trevor N. Collingwood | Laurence Cooper | Philip D. Gregory | Michael C. Holmes | Jeffrey C. Miller | Edward J. Rebar | Andreas Reik | Fyodor Urnov","Board of Regents, University of Texas System | SANGAMO BIOSCIENCES, INC.","C12N15/00 | C12P21/00 | C07K14/74","435/455 | 435/252.3 | 530/350 | 435/440 | 435/69.1","C07K14/70539 | A61K35/17 | C12N15/907 | C07K2319/81 | C12N2800/80","7","7","US9833479 | US9629877 | US9273283 | US9663763 | US9616090 | US9181527 | US9701758","33","US7253273 | US6979539 | US7153949 | US6503717 | US6200759 | US6013453 | US5356802 | US7070934 | US6607882 | US6242568 | US5925523 | US7361635 | US6410248 | US6794136 | US5436150 | US5789538 | US7262054 | US7163824 | US7067317 | US6140466 | US6479626 | US6140081 | US6599692 | US6689558 | US6903185 | US7013219 | US6007988 | US6933113 | US7030215 | US6453242 | US6824978 | US5487994 | US6534261"
"US8956828","Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases","Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided.","2010","2010-11-10","2015","2015-02-17","""An isolated zinc finger nuclease (ZFN) comprisinga zinc finger protein that binds to a target site in a T-cell receptor (TCR) gene, wherein the zinc finger protein comprises four, five or six zinc finger domains ordered F1 to F4 for four-finger proteins, F1 to F5 for five-finger proteins and F1 to F6 for six-finger proteins, wherein the zinc finger protein is selected from the group consisting of a protein comprising the following amino acid sequences in the recognition regions:(i) F1: QSGDLTR (SEQ ID NO:2);F2: QRTHLKA (SEQ ID NO:3);F3: QSGDRNK (SEQ ID NO: 4);F4: DRSNLSR (SEQ ID NO:5); andF5: RSDALTQ (SEQ ID NO:6);(ii) F1: TSGSLSR (SEQ ID NO:8);F2: QSSVRNS (SEQ ID NO:9);F3: RSDNLST (SEQ ID NO:10);F4: DRSALAR (SEQ ID NO:11); andF5: LKQNLDA (SEQ ID NO:12);(iii) F1: DRSALSR (SEQ ID NO:14);F2: QSGHLSR (SEQ ID NO:15);F3: DRSDLSR (SEQ ID NO:16);F4: RSDALSR (SEQ ID NO:17); andF5: DRSDLSR (SEQ ID NO:16);(iv) F1: DRSNLSR (SEQ ID NO:5);F2: QKTSLQA (SEQ ID NO:19);F3: DRSALSR (SEQ ID NO:14);F4: QSGNLAR (SEQ ID NO:20);F5: GKEELNE (SEQ ID NO:21); andF6: RSSDLSR (SEQ ID NO:22);(v) F1: GNVDLIE (SEQ ID NO:24);F2: RSSNLSR (SEQ ID NO:25);F3: RSDALSV (SEQ ID NO:26);F4: DSSHRTR (SEQ ID NO:27); andF5: WRSCRSA (SEQ ID NO:28);(vi) F1: DSSDRKK (SEQ ID NO:30);F2: RSDNLSV (SEQ ID NO:31);F3: RRFILRG (SEQ ID NO:32);F4: QSGDLTR (SEQ ID NO:2); andF5: TSGSLTR (SEQ ID NO:33);(vii) F1: QSGDLTR (SEQ ID NO:2);F2: QTSTLSK (SEQ ID NO:35);F3: QSGHLSR (SEQ ID NO:15);F4: DRSDLSR (SEQ ID NO:16); andF5: RSDALAR (SEQ ID NO:36);(viii) F1: QSGDLTR (SEQ ID NO:2);F2: WRSSLAS (SEQ ID NO:38);F3: QSGDLTR (SEQ ID NO:2);F4: HKWVLRQ (SEQ ID NO:39); andF5: DRSNLTR (SEQ ID NO:40);(ix) F1: QSGDLTR (SEQ ID NO:2);F2: QWGTRYR (SEQ ID NO:42);F3: ERGTLAR (SEQ ID NO:43);F4: RSDNLRE (SEQ ID NO:44);F5: QSGDLTR (SEQ ID NO:2); andF6: TSGSLTR (SEQ ID NO:33);(x) F1: RSAHLSR (SEQ ID NO:46);F2: DRSDLSR (SEQ ID NO:16);F3: RSDHLSV (SEQ ID NO:47); andF4: QNNHRIT (SEQ ID NO:48);(xi) F1: QRSNLVR (SEQ ID NO:50);F2: RNDDRKK (SEQ ID NO:51);F3: TSGNLTR (SEQ ID NO:52); andF4: TSANLSR (SEQ ID NO:53);(xii) F1: DRSTLRQ (SEQ ID NO:55);F2: QRSNLVR (SEQ ID NO:50);F3: RNDDRKK (SEQ ID NO:51);F4: RSAHLSR (SEQ ID NO:46); andF5: QSGHLSR (SEQ ID NO:15);(xiii) F1: QRSNLVR (SEQ ID NO:50);F2: RNDDRKK (SEQ ID NO:51);F3: QSGHLAR (SEQ ID NO:56); andF4: QSGHLSR (SEQ ID NO:15);(xiv) F1: RSAHLSR (SEQ ID NO:46);F2: DRSDLSR (SEQ ID NO:16);F3: RSDHLSV (SEQ ID NO:47); andF4: QNNHRIT (SEQ ID NO:48);(xv) F1: RSDVLSA (SEQ ID NO:59);F2: DRSNRIK (SEQ ID NO:60);F3: RSDVLSE (SEQ ID NO:61);F4: QSGNLAR (SEQ ID NO:20); andF5: QSGSLTR (SEQ ID NO:62);(xvi) F1: RSDHLST (SEQ ID NO:64);F2: RSDNLTR (SEQ ID NO:65);F3: DRSNLSR (SEQ ID NO:5);F4: TSSNRKT (SEQ ID NO:66);F5: RSANLAR (SEQ ID NO:67);F6: RNDDRKK (SEQ ID NO:51);(xvii) F1: RSDHLST (SEQ ID NO:64);F2: RSDNLTR (SEQ ID NO:65);F3: DRSNLSR (SEQ ID NO:5);F4: LQFNRNQ (SEQ ID NO:68);F5: RSANLAR (SEQ ID NO:67); andF6: RNDDRKK (SEQ ID NO:51);(xviii) F1: RSDHLST (SEQ ID NO:64);F2: RSDNLTR (SEQ ID NO:65);F3: DSSNLSR (SEQ ID NO:69):F4: LRFNLSN (SEQ ID NO:70);F5: RSANLAR (SEQ ID NO:67); andF6: RNDDRKK (SEQ ID NO:51);(xix) F1: RSDHLST (SEQ ID NO:64);F2: RSDNLTR (SEQ ID NO:65);F3: DSSNLSR (SEQ ID NO:69);F4: LHFQLTG (SEQ ID NO:71);F5: RSANLAR (SEQ ID NO:67); andF6: RNDDRKK (SEQ ID NO:51);(xx) F1: RSDVLSA (SEQ ID NO:59);F2: DRSNRIK (SEQ ID NO:60);F3: RSDVLSE (SEQ ID NO:61);F4: QSGNLAR (SEQ ID NO:20); andF5: QSGSLTR (SEQ ID NO:62);(xxi) F1: DRSNLSR (SEQ ID NO:5);F2: LKFALAN (SEQ ID NO:72);F3: RSDVLSE (SEQ ID NO:61);F4: QSGNLAR (SEQ ID NO:20); andF5: QSGSLTR (SEQ ID NO:62);(xxii) F1: RSDVLSA (SEQ ID NO:59);F2: DRSNRIK (SEQ ID NO:60);F3: RSDVLSE (SEQ ID NO:61);F4: QSGNLAR (SEQ ID NO:20); andF5: QSGALAR (SEQ ID NO:73); and(xxiii) F1: RLSVLTI (SEQ ID NO:74);F2: DRANLTR (SEQ ID NO:75);F3: RSDVLSE (SEQ ID NO:61);F4: QSGNLAR (SEQ ID NO:20); andF5: QSGALAR (SEQ ID NO:73);and a cleavage domain.""","Maria Chiara Bonini | Pietro Genovese | Philip D. Gregory | Michael C. Holmes | Luigi Naldini | David Paschon | Elena Provasi | Lei Hu Zhang","SANGAMO BIOSCIENCES, INC. | OSPEDALE SAN RAFFAELE S.R.L.","C12N9/22 | A61K38/00 | A61K35/00 | C07H21/04 | C12P21/06","435/455 | 435/196 | 530/350 | 435/352 | 536/234 | 536/232 | 435/69.1 | 536/23.2 | 536/23.4","A61K35/28 | A61K35/17 | C07K14/7051 | C12N9/22 | C12N15/01 | A61K35/00 | A61K38/00 | C07K2319/81 | C07K2319/95","7","7","US9663763 | US9273283 | US9816074 | US9616090 | US9181527 | US9629877 | US9701758","23","US6933113 | US6503717 | US6007988 | US5925523 | US6410248 | US7163824 | US5789538 | US5487994 | US6013453 | US5436150 | US6453242 | US6824978 | US6599692 | US6607882 | US6689558 | US6200759 | US6242568 | US5356802 | US6140466 | US7013219 | US6140081 | US6534261 | US6979539"
"US9005973","Targeted genomic modification with partially single-stranded donor molecules","Disclosed herein are donor molecules comprising single-stranded complementary regions flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.","2011","2011-07-08","2015","2015-04-14","""A method of non-homologous end joining (NHEJ)-mediated targeted integration of a linear nucleic acid molecule into the genome of a mammalian cell, the method comprising:introducing a linear nucleic acid molecule into the mammalian cell, the linear nucleic acid molecule comprising a double-stranded sequence of interest having first and second ends and first and second single-stranded nucleotides between 1 and 10 nucleotides in length at the first and second ends of the double-stranded sequence; andcreating a double-stranded break using a nuclease in an endogenous locus of the genome of the mammalian cell such that the linear nucleic acid molecule is integrated at the site of the double-stranded break and further wherein the nuclease comprises a TALE domain and the first and second single-stranded nucleotides are 100% complementary to the overhangs of the double-stranded break in the mammalian genome created by the nuclease; andannealing the first and second single-stranded nucleotides of the donor to the overhangs of the double-stranded break in the mammalian genome, thereby directly integrating the donor at the site of double-stranded break by NHEJ-mediated targeted integration.""","Gregory J. Cost | Dmitry M. Guschin | Fyodor Urnov","SANGAMO BIOSCIENCES, INC.","C12N15/00 | C12N15/90 | C12N9/22 | C12P21/06 | C12N15/87","435/463 | 435/455 | 435/691 | 435/440 | 435/69.1","C12N15/902 | C12N9/22 | C12N15/907 | C07K2319/80 | C07K2319/81","1","1","US9616090","28","US6140466 | US6903185 | US6453242 | US6599692 | US6410248 | US7153949 | US6689558 | US6607882 | US6528313 | US6007988 | US6200759 | US6933113 | US5356802 | US5789538 | US6140081 | US5487994 | US6824978 | US6528314 | US6242568 | US5436150 | US7163824 | US6979539 | US6013453 | US6534261 | US7013219 | US5925523 | US6479626 | US6503717"
